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Modulation of Neural Plasticity by the ADAMTSs (a Disintegrin and
Metalloproteinase with Thrombospondin Motifs)
Michelle Hamel
ABSTRACT
Aggregating proteoglycans (PG) bearing chondroitin sulfate (CS) side
chains are well-known inhibitors of neural plasticity and associate with
hyaluronan and tenascin-R to form a complex of extracellular matrix (ECM) in the
central nervous system (CNS). Little is known about whether proteolytic
cleavage of the core protein affects neural plasticity. Several members of the
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family
of metalloproteinases are glutamyl-endopeptidases that cleave aggregating PGs.
Our initial studies determined that neural cultures secrete a brevican-containing
matrix, and that these neural cultures also produced ADAMTS4, a protease that
cleaves brevican. Furthermore, this brevican-containing matrix in astrocytes
could be modulated by treatment with transforming growth factor β (TGFβ)
through the inhibition of the activity of the ADAMTSs.
Once it was established that neural cultures produce a brevican-rich
matrix, we sought to utilize this matrix to determine whether cleavage of
aggregating PGs, especially brevican, by the ADAMTSs influences neurite
outgrowth in cultured neurons. Transfection of rat neurons with ADAMTS4 cDNA
induced longer neurites, and interestingly, this effect proved to be independent of
iv

the proteolytic action of the ADAMTSs. Addition of recombinant ADAMTS4 or
ADAMTS5 protein to immature neuronal cultures similarly enhanced neurite
extension, an action dependent on the activation of extracellular signal-related
kinase (ERK)1/2 (MAP kinase 42/44), resulting in the first evidence that
ADAMTSs may induce intracellular signaling events.
Studies of dendritic spine morphology and levels of synaptic proteins in
response to ADAMTS4 treatment were also undertaken. Neuronal cultures
treated with ADAMTS4 showed increased length of dendritic spines and
increased percent of immature spines detected. A concurrent decrease in postsynaptic protein staining was detected on the neurites of young neurons
overexpressing ADAMTS4 or expressing proteolytically-inactive mutant
ADAMTS4 protein. Thus, ADAMTS4 may promote plasticity in neurons in vitro
by preventing the formation, maturation, and/or stabilization of synapses.
Overall, these experiments provide evidence that implicate the ADAMTSs as
mediators of neural plasticity, and while primarily known only as proteases, these
studies demonstrate that the ADAMTSs exert actions distinct from these
proteolytic properties that require the induction of intracellular signaling events.
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Introduction

Neural plasticity and proteoglycans
Neural plasticity is the broad term used to describe the processes that
occur in the CNS to facilitate the formation of new neural connections. This is a
complex process involving proliferation and migration of cells, neuritic sprouting
and synaptogenesis that occurs between the newly extended processes.
Plasticity can be defined as functional changes that occur in neurons. The
developing brain is highly plastic, whereas plastic changes in mature adult brain
are more limited but may readily take place in certain regions including
hippocampus and olfactory bulb. This is important in terms of injury to the adult
brain, where a plastic response, if activated, could lead to functional recovery.
Extensive neurite outgrowth occurs during the development of the CNS,
and also in response to injury, although to a much greater extent in the peripheral
nervous system (PNS) compared to the CNS. Sprouting neurites must traverse
a circuitous route and penetrate a multifarious extracellular matrix to reach and
innervate their targets. Proteoglycans (PG), more specifically those of the
lectican family, are a major component of this matrix and function in pathfinding,
cell adhesion and migration. It is well established that PGs are inhibitors of
neurite outgrowth. Lectican expression is extensive in the brain throughout life.
1

Early in development, PGs function in axonal pathfinding as inhibitory guidance
cues and act as barriers to outgrowing neurites (Snow et al., 1991; Kubota et al.,
1999; Ichijo, 2004; Kantor et al., 2004). Chondroitin sulfate (CS) chains that are
covalently linked to the central domain of the PG aid in inhibiting neurite
outgrowth, and removing these chains allows for increased plasticity (Pizzorusso
et al., 2002), and in other cases, pathfinding errors (Brittis et al., 1992; Bernhardt
and Schachner, 2000; Masuda et al., 2004). In fact, removing the
glycosaminoglycan (GAG) chains from the PG caused a plastic dominance shift
in the visual cortex of the adult animal undergoing monocular deprivation
(Pizzorusso et al., 2002). Many studies implicate the CS moieties in the ability of
the PG to inhibit neurite outgrowth since treatment of PGs with the experimental
enzyme that degrades CS chains, chondroitinase ABC, increases plasticity. It
should be noted, however, that chondroitinase ABC degrades hyaluronan, a
large high molecular weight GAG in the ECM, and thus, this effect may play a
role in the reactivation of plasticity seen in these experiments. Other studies
have shown that the core protein retains a degree of inhibition, although not as
great at the intact PG, after CS GAG chain removal (Schmalfeldt et al., 2000;
Ughrin et al., 2003). Conversely, limited evidence indicates that PGs with little
GAG chain substitution and those PGs bearing heparan sulfate (HS) chains may
actually support neurite outgrowth (Hantaz-Ambroise et al., 1987; Kim et al.,
2003). In vitro studies have shown that upon contacting PGs, growth cones do
not collapse, but are rather redirected on another path (Snow et al., 2001). In
fact, growing neurons in the presence of CS-containing PG results in increased
2

axonal fasciculation (Snow et al., 2003). Since the core protein does retain the
ability to attenuate neurite outgrowth, attempts have been made to implicate this
portion of the molecule in this function as increased neuritic growth is observed
after core protein cleavage (Zuo et al., 1998). To date, there is no unifying theory
as to how PGs inhibit neurite outgrowth, and in fact, several possible
mechanisms have been proposed to explain the ability of the CS-containing PG
to attenuate neurite outgrowth so exquisitely. These proposed mechanisms
range from receptor mediated processes to sequestering growth factors. There
may be an unknown receptor that binds PGs to activate neuritic growth inhibiting
processes (Carulli et al., 2005). Another theory is that CSPGs bind growthsupporting molecules to sequester these factors (Bovolenta and FernaudEspinosa, 2000; Deepa et al., 2002; Carulli et al., 2005), or block the receptors
for growth factors (Snow and Letourneau, 1992; Smith-Thomas et al., 1994;
McKeon et al., 1995; Carulli et al., 2005). Instead of blocking growth promoting
processes, it may be that PGs aid growth inhibitory processes. PGs may direct
inhibitory molecules to their site of action (Emerling and Lander, 1996; Carulli et
al., 2005) or may even bind receptors that activate cell signals to block neurite
outgrowth (Carulli et al., 2005). There are many possible mechanisms but no
convincing data to this date to determine the mechanism of action of the PG in
inhibiting neurite outgrowth.
While PGs are important in pathfinding and development, they are also
highly expressed in the glial scar, the accumulation of reactive astrocytes and
deposition of ECM components that occurs in response to injury to restrict the
3

growth of axons into a damaged area of the CNS. The CNS responds to injury
by recruiting cell types like microglia and oligodendrocyte precursors to the injury
site. These cells work in concert with reactive astrocytes to express several
growth-restricting molecules, one of the most highly expressed being lecticans
(Tang et al., 2003). Several other inhibitory components are expressed as well,
like the glycoprotein tenascin and the myelin-associated inhibitor Nogo-A (Asher
et al., 2001). The application of chondroitinase ABC to degrade the CS chains of
PGs expressed in response to injury such as nigrostriatal tract axotomy or spinal
cord lesion results in increased axonal regeneration (Moon et al., 2001; Bradbury
et al., 2002). Therefore, due to their expression pattern and well known role in
restricting neuritic growth, the modulation of PGs is promising as a means to
activate plasticity in the adult CNS.
When attempting to enhance plasticity in the CNS, neurite outgrowth is
important, but insignificant if these new axons do not form functional connections.
Currently, interest is increasing as to how ECM components influence changes in
the morphology of synapses, rather than changes in the conductance of the
neuron. Dendritic spines, the site for excitatory neurotransmission in the CNS,
are a very common method to measure alterations in synaptic morphology since
these protrusions show some degree of morphological plasticity in adult CNS.
An array of various proteins is important in regulating the formation and alteration
of dendritic spines, which are highly enriched in actin and thus highly motile
structures. Lecticans surround dendritic spines except at the synapse, however,
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their function in synaptic modulation has been speculated to be important, and is
supported by indirect evidence.
Lecticans and perineuronal nets
Perineuronal nets (PNN), which ensheathe certain neurons to form an
isolated microenvironment, are thought to be important in the regulation of
synaptic plasticity. Neurons and glia secrete the components of the PNN (Celio
and Blumcke, 1994). In the brain, ECM localizes to the intracellular spaces
between neurons and glia and also coats the neuronal surface, and is deposited
in neuropil and white matter. The four proteoglycans of the lectican family,
aggrecan, neurocan, versican and brevican share significant homology and are
the chief components in brain ECM of neuropil and PNNs. The four lecticans
share homologous structural motifs, namely the G1 globular domain located at
the N-terminus, and the G3 globular domain located at the C-terminus. There is
also a non-homologous central domain that contains varying numbers of
attachment sites for CS chains. The lecticans differ mainly in their lengths,
degree of CS attachment and expression pattern in the brain. The G1 domain
contains binding motifs for hyaluronan and the G3 domain binds tenascin, both of
which are found in PNNs (Yamaguchi, 2000). Several studies have
demonstrated binding as well as co-localization of the lecticans with hyaluronan
and tenascin, and hyaluronan and tenascin are part of PNNs (Aspberg et al.,
1997; Hagihara et al., 1999). Thus, it is thought that the binding of these three
components form the contents of the PNN. The tightness of the lattice can be
altered by substituting lecticans of differing lengths or by proteolytic cleavage of
5

the lectican (Yamaguchi, 2000). Indeed, lectican protein fragments of similar
size are detected in many tissues, including the brain, suggesting that there is a
conserved sequence at which extracellular proteolytic cleavage occurs.
Lecticans are detected as components of PNNs and in region-specific
staining patterns in the neuropil (Bignami et al., 1993; Bertolotto et al., 1996).
PNNs typically envelope GABAergic interneurons, although PNNs are not limited
to these neurons. Staining of lecticans on PNNs and in the neuropil correlate
with staining of hyaluronan and tenascin in the mouse hippocampus, lending
further credence to the idea that these components interact to form a lattice in
the ECM (Bruckner et al., 2003).
Evidence indicates that the lectican/tenascin/hyaluronan complex does
have functional relevance in the brain. Mice deficient in tenascin-R expression
results in abnormal distribution of ECM components, including brevican, although
there is no structural change in the synapse. There is altered long term
potentiation (LTP) in tenascin-R deficient mice, and this is similar to changes that
occur in a brevican knock-out mouse (Saghatelyan et al., 2001; Brakebusch et
al., 2002). The C-terminal G3 domain of the lecticans contain attachment sites
for carbohydrate moieties like tenascin and sulfoglucuronyl glycolipids. This
binding with non GAG chain-containing brevican promotes neuronal adhesion
and neurite outgrowth (Miura et al., 2001), and hyaluronan associated adhesive
cues influence positioning of entorhinal fibers in the hippocampus (Forster et al.,
2001). Thus, PGs and ECM cues may be important in neural plasticity in the
adult brain.
6

The lecticans brevican, versican V2 and aggrecan are expressed after the
dendritic pruning critical period and levels remain high in the adult when
synapses are cemented. Additionally, lecticans are deposited around synapses,
and these facts taken together offer evidence that lecticans may be important in
synaptic stabilization. Lectican expression is developmentally regulated with
neurocan and versican V1 being expressed at high levels in the young animal,
while brevican, versican V2 and aggrecan are expressed beginning at postnatal
day 10 in the rat with levels peaking at postnatal day 100. These high levels
persist throughout life (Milev et al., 1998). Brevican in particular is highly
expressed in the neuropil of adult brain and localizes perisynaptically, leading to
the hypothesis that brevican is important in the stabilization of synapses
(Hockfield et al., 1990; Koppe et al., 1997; Yamaguchi, 2000; Mayer et al., 2005).
The presence of brevican is thought to render a synapse more static and
resistant to plasticity, and may even inhibit the formation of new synapses.
Brevican is a unique member of the lectican family of PGs, and exists as a “parttime” proteoglycan, and in fact, about 50% of the brevican in the brain exists
without any CS or other sugars (Yamada et al., 1994). Additionally, brevican is
alternatively spliced to produce a GPI signal sequence that results in the protein
covalently tethered to the membrane (Seidenbecher et al., 1995), although the
cell type producing GPI brevican remains unclear (Seidenbecher et al., 1998;
Jaworski et al., 1999). The GPI and secreted forms of brevican are concentrated
in synaptic fractions and associate with lipid rafts (Seidenbecher et al., 2002).
Interestingly, brevican knock-out mice show no obvious deficits in behavior or
7

learning, but have a phenotype of impaired LTP. It has not been examined,
however, whether a compensatory increase in other lectican family members
resulted from deficiencies in brevican and may explain why these mice have little
neurological phenotype. Similarly, LTP can be impaired by infusing anti-brevican
antibodies into the brains of wild-type mice (Brakebusch et al., 2002). At any
rate, impaired LTP certainly demonstrates that brevican is important for the
formation of new memories at the molecular level. A quadruple knockout mouse
was created recently lacking expression of brevican, neurocan, tenascin-R and
tenascin-C. The only abnormality displayed by this mouse is increased fibulin
expression that assumedly is compensating for the loss of tenascin (Rauch et al.,
2005), but further characterization of these animals is necessary to fully
understand the phenotype.
Other PG families demonstrate a role in synaptogenesis, suggesting that
molecules similar to PGs with CS side chains may also modulate synapse
formation. Enzymatically degrading the HS chains in neuronal cultures disrupts
the action of neural cell adhesion molecule (NCAM) to activate synaptogenesis
(Dityatev et al., 2004). Overexpressing the HSPG syndecan-2 induces mature
dendritic spine formation in immature neuronal cultures presumably by
interacting with Eph receptors (Ethell and Yamaguchi, 1999). In the PNS, agrin,
a HSPG, is essential for proper development and function of the neuromuscular
junction (Werle and VanSaun, 2003). Since the mechanism of HS in synaptic
function is unclear, it is difficult to speculate whether CSPGs could act in a similar
fashion, although it is reasonable to believe that they may.
8

Degradation of extracellular matrix
In addition to a role for GAG side chains, perhaps modulating the
inhibitory ECM by cleavage of the PG core protein through endogenous
proteases could lead to altered synaptic plasticity. Proteolytic cleavage and
degradation of ECM occurs through proteases of three major families: the matrix
metalloproteinases (MMP), the plasminogen activator-plasmin system and the
ADAMTSs. The MMPs are Ca++ and Zn++ dependent proteases that cleave ECM
and are latent pro-proteases. As degradation of the matrix needs to be tightly
controlled, their regulation occurs through several mechanisms. There are
controls in gene expression, activation of the pro-protease and inhibition of the
protease with the tissue inhibitors of metalloproteinases (TIMP). Furthermore,
MMPs, as well as ADAMTSs and ADAMs are maintained in their inactive state by
a Zn++ non-covalently bound to an unpaired cysteine residue, known as a
“cysteine switch” in the pro-domain of the protease. In vitro, autocatalysis occurs
when the Zn++-cysteine interaction is disturbed by free radicals, organomercurial
compounds or proteolysis, resulting in an activated protease. Many studies have
revealed changes in MMP expression in CNS injury and pathology models (Yong
et al., 2001), and mounting evidence indicates both a detrimental and beneficial
role for the MMPs.
The ADAMTSs are the most recently cloned family of ECM-degrading
proteases. They are similar in structure to the ADAM family of proteases and cell
surface adhesion proteins. The ADAMTSs cleave PGs, including aggrecan
(Tortorella et al., 1999), brevican (Matthews et al., 2000); and versican V2
9

(Westling et al., 2004). Currently, there are 19 members described that belong to
this family of proteins with widespread expression, and several members are
expressed and proteolytically active in brain. Certain ADAMTSs are secreted as
latent pro-proteases and activated by cleavage at a furin-like site in the prodomain of the molecule. ADAMTSs are secreted and anchor to the cell surface
or ECM by their C-terminal spacer domain or thrombospondin (TSP) repeats,
which bind GAG chains on HS or glycolipids (Nagase and Kashiwagi, 2003).
The TSP motifs, along with the spacer region, mediate lectican (and presumably
other substrates) binding to protease (Kashiwagi et al., 2004, Fig. 1).

Figure. 1: Protein Domains of ADAMTS4. ADAMTS family members contain
several conserved protein domains important in protease functionality. These
domains include an N-terminal pro-domain that is cleaved by a furin-like protease
upon secretion to aid in activation of the enzyme, a catalytic domain that is
responsible for proteolytic capacity, a disintegrin domain that is similar to snake
venom reprolysins (Dis), a Thrombospondin type I motif (Tsp), cysteine rich
region (Cys) and a C-terminal spacer domain that is successively cleaved to
reveal lower molecular weight isoforms of ADAMTS4.
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Figure. 1: Protein Domains of ADAMTS4.

ADAMTSs cleave aggrecan, versican and brevican at a conserved
sequence located near the N-terminus of the GAG chain containing central
domain (Yamaguchi, 2000). Interestingly, this is the only portion of the central
domain where the lecticans share a high degree of homology. ADAMTS4 and
ADAMTS1 mRNA are induced in rat brain after kainic acid injection (Yuan et al.,
2002). Little is known about ADAMTS expression in CNS pathology states or if
cleavage of the PG results in altered biological function of the PG. Our
laboratory demonstrated that ECL increases ADAMTS4 expression with a
concomitant increase in the ADAMTS cleaved fragment of brevican (Yuan et al.,
11

2002; Mayer et al., 2005). Recent findings also indicate that versican’s G3
proteolytically derived fragment increases neurite outgrowth and results in the
activation of extracellular signal-related kinase (ERK) 1/2 (Xiang et al., 2006),
lending credence to the belief that the ADAMTSs indeed have important
physiological function. Additionally, treating rat astrocytes with ß amyloid
increases the ADAMTS4 transcript (Satoh et al., 2000). TIMPs are endogenous
inhibitors of MMPs and the ADAMTSs (Nagase and Brew, 2003) and TIMP
expression in the brain is increased in response to injury. TIMP-1 has been
implicated as an immediate early gene in response to the excitotoxin, kainate
(Jaworski, 2000). TIMP-3 potently inhibits the action of ADAMTS4 (Kashiwagi et
al., 2001).
In in vitro situations, ADAMTSs are nearly always found associated with
cell membranes, and this suggests that members of this family bind cell proteins
or extracellular matrix proteins that are in close association with the cell surface,
and it is largely unknown whether these proteins are transmembrane, GPI-linked
or localized near the cell surface. The TSP repeats aid in ADAMTS binding to
HS (Kuno and Matsushima, 1998), and in fact, the HSPG syndecan-1 was
recently shown to bind the shortest C-terminally processed fragment of
ADAMTS4 in chondrosarcoma cells. Sulfated GAG chains affect this binding,
and in fact, both HS and CS of syndecan were required for ADAMTS4 to bind
(Gao et al., 2004). Syndecan-1 may direct ADAMTS4 to its receptor at the cell
surface or ADAMTS4 may modulate syndecan-1 signaling itself. Another
member of the syndecan family, syndecan-2, is highly expressed by mature
12

dentate granule neurons and neurons from other brain regions at post-synaptic
sites where it is linked to CASK/LIN-2 scaffolding proteins also involved in
signaling (Hsueh and Sheng, 1999). Syndecan signaling induces maturation of
dendritic spines (Ethell and Yamaguchi, 1999; Ethell et al., 2001). Thus,
modulation of syndecan signaling by ADAMTS4 could potentially alter synaptic
function and plasticity.
Recent advances have shown the involvement of ECM proteases in
pathological processes in the nervous system. Although most of this research is
descriptive, showing changes in levels or localization of mRNA and/or protein,
this early progress is encouraging further probing into the effects of ECMdegrading proteases in disease processes since these studies show time
dependent changes in these proteases in response to injury. While these early
studies are necessary to lay the foundation for the edifice of discovery, further
studies are necessary to reveal the action of these proteases in injury and
plasticity since the expression of the protease is often coupled with the
expression of its inhibitor, the TIMPs, and thus simply noting the expression of an
ADAMTS does not necessarily mean it is proteolytically active. Disease models
yield clues that ADAMTSs are physiologically relevant, and the studies presented
here seek to determine whether brevican cleavage by ADAMTSs can modulate
neurite outgrowth and synaptogenesis in vitro.

13

Chapter 1: Altered Production and Proteolytic Processing of Brevican by
Transforming Growth Factor ß in Cultured Astrocytes

Abstract
Brevican, a proteoglycan of the lectican family, inhibits neurite outgrowth
and may also stabilize synapses. Little is known about its expression or function
in vitro. This study seeks to determine whether a brevican-containing matrix is
present in neural cultures, and if so, how the production of brevican may be
modulated. To accomplish this, the content of brevican and its proteolytic
fragments were measured in primary cultures of neurons, astrocytes and
microglia after treatment with cytokines. These experiments revealed that
astrocytes and neurons express several isoforms of brevican, whereas microglia
do not produce this proteoglycan. Cleavage fragments of brevican were found
primarily in neuronal and astrocyte culture medium. ADAMTS4 (a disintegrin and
metalloproteinase with thrombospondin motifs), a protease that selectively
cleaves lecticans, was detected in cultures of neurons, astrocytes and microglia.
When astrocytes were challenged with various cytokines, it was found that
treatment with transforming growth factor β (TGFβ) resulted in a marked increase
in intact brevican in the culture medium that was accompanied by a trend for a
decrease in ADAMTS-generated fragments of brevican and apparent ADAMTS
14

activity. Thus, TGFβ may play a role in neuronal plasticity through its regulation
of brevican and the activity of the ADAMTSs.

Introduction
In the nervous system, extracellular matrix (ECM) exists in the neuropil
and in discrete reticular networks around the surface of neurons, termed
perineuronal nets. The matrix is thought to exist as a complex of aggregated
molecules whose components include hyaluronan, tenascin-R and one or more
members of the lectican family of proteoglycans (PGs). Each of the PGs in the
lectican family, brevican, versican, aggrecan and neurocan, are variably
substituted with chondroitin sulfate (CS) chains in the central domain of the core
protein, and the globular N-terminus binds hyaluronan whereas the C-terminus
binds tenascin-R (Yamaguchi 2000). Among the lecticans, brevican is the most
abundant PG in the ECM of the central nervous system (CNS), and is secreted
by astrocytes and neurons (Seidenbecher et al. 1998; Jaworski et al. 1999)
where it is located perisynaptically (Hagihara et al. 1999) in association with
synaptic proteins (Seidenbecher et al. 2002). This aggregated complex of matrix
is thought to confer stability in neural networks and inhibit plasticity after injury
(Rhodes and Fawcett 2004). Interestingly, treatment of the tissue with
chondroitinase markedly improves plasticity, including neurite outgrowth, after
injury in vivo (Moon et al. 2001).
In adult CNS, secreted brevican is found as a CS-substituted, high
molecular weight isoform (Fig. 2A), a 145 kD unsubstituted core protein (Fig. 2B),
15

and as 55 (Fig. 2C) and 80 kD (Fig. 2D, 2E) N- and C-terminal fragments as a
result of proteolytic cleavage (Yamada et al. 1994). The major family of
proteases responsible for the generation of these lower molecular weight
fragments is the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family, (Tortorella et al. 1999; Matthews et al. 2000),
although the matrix metalloproteinases (MMPs) are also able to cleave lecticans
(Nakamura et al., 2000). The cleavage of brevican and other lecticans by the
ADAMTSs may result in a loosening of the lectican-hyaluronan-tenascin matrix,
thus providing conditions more suitable for neuronal plasticity, yet little evidence
supports such a notion (Yuan et al. 2002).

Figure 2. Schematic demonstrating isoforms, cleavage products, and antibody
recognition sites of brevican.
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Figure 2. Schematic demonstrating isoforms, cleavage products, and antibody
recognition sites of brevican. Brevican exists as a >145 kD proteoglycan that
contains variable numbers (1-3) of CS chains attached to the core protein (A); a
145 kD core protein devoid of CS chains (B); a 55 kD N-terminal fragment
derived from ADAMTS cleavage that generates the C-terminal neoepitope
sequence EAVESE (C); a > 80 kD fragment containing CS chains (D) or an 80
kD C-terminal fragment (E) that are the proteolytic cohorts to the 55 kD fragment.
Proteolytic cleavage of brevican is not limited to the ADAMTSs and likely
includes cleavage by the MMPs which also generates a ~55 kD product. The
anti-EAVESE antibody recognizes the neoepitope sequence generated by
ADAMTS cleavage at the C-terminus of the 55 kD fragment (C). The antibrevican antibody recognizes a sequence in the N-terminal globular domain of
brevican and recognizes the forms illustrated in (A), (B) and (C).

Although there is substantial data about brevican and its expression and
localization in the CNS (Bruckner et al., 2003), little is known about the
production of brevican in vitro, and nothing is known of its association with an in
vitro matrix. Brevican mRNA transcript was detected in cultures of cerebellar
astrocytes, but not in neurons derived from cerebral cortex (Yamada et al. 1994).
Other efforts have been made to mimic an in vivo matrix by adding exogenous
components of the matrix aggregate to cell cultures, especially astrocyte cultures
(Deyst and Toole 1995; Maleski and Hockfield 1997). The related proteoglycan,
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neurocan, was found in conditioned medium and as a pericellular, substrate
bound ECM protein in astrocytes in culture (Asher et al., 2000).
We were interested in whether brevican is produced by primary astrocytes
in culture, whether it is associated with any complex matrix present in the
cultures and whether factors such as cytokines may regulate brevican production
in astrocytes in vitro. Considerable evidence indicates that the cytokine,
transforming growth factor (TGF)β is an important regulator of multiple matrix
components including tenascin, fibronectin, collagen, thrombospondin and
especially PGs (Taipale et al. 1998). In culture systems from a variety of tissues
including lung fibroblasts (Venkatesan et al. 2002), prostatic stromal cells (Sakko
et al. 2001), bovine tendon tissue explants (Robbins et al. 1997), human
fibroblasts (Kahari et al. 1991), and articular chondrocytes (Morales and Roberts
1988; Morales et al. 1991), TGFβ markedly stimulated the production of PGs. In
addition, when endogenous TGFβ activity was inhibited by RNA interference
(RNAi) or antibody, there was a significant decline in PG production or the
development of a pericellular matrix (Deyst and Toole 1995; Merrilees et al.
2000). The aim of the present study was to characterize the secretion of
brevican isoforms by cells of the nervous system, especially astrocytes, and to
identify factors that regulate the secretion of brevican in astrocytes.

18

Materials and Methods
Animals and Materials
All animal protocols used in this study were approved by the Institutional
Animal Care and Use Committee at the University of South Florida. Timed
pregnant Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN),
Taconic (Germantown, NY) or Charles River Laboratories (Wilmington, MA).
Human recombinant TGFβ1, human recombinant interleukin-(IL)-1β and human
recombinant vascular endothelial growth factor (VEGF) were obtained from
PeproTech (Rocky Hill, NJ). Tissue culture media, animal sera, trypsin and
antibiotic/antimycotic solution were purchased from Mediatech (Herndon, VA) or
Gibco Invitrogen (Carlsbad, CA). Cell culture plasticware used in these
experiments was from Costar (Acton, MA.) or Sarstedt (Nümbrecht, Germany),
supplies for electrophoresis were obtained from Invitrogen (Carlsbad, CA) and all
other general chemicals were obtained from Sigma-Aldrich (St. Louis, MO).

Enriched Cultures of Rat Astrocytes, Neurons and Microglia
For mixed glial cultures, one to three day-old Sprague-Dawley rat pups
were euthanized and whole brains removed from the skull. The meninges and
cerebellum were removed in sterile isotonic buffer (137mM NaCl, 5.4mM KCl,
0.17mM Na2HPO4, 0.22mM KH2PO4, 5.5mM glucose, 59mM sucrose), chopped
into 1mm cubes, and the tissue incubated in 0.25% trypsin, 0.05% EDTA at 37°
for 12 minutes, vortexing every 4 minutes. The disrupted tissue was then
triturated, the cells centrifuged and recovered, and 1x107 cells plated on poly-l19

lysine-pre-coated (Sigma-Aldrich, St. Louis, MO) 100mm dishes in 10ml of
Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% horse serum,
2.5% fetal bovine serum and 1% antibiotic-antimycotic solution. Medium was
changed after four days of culture, and after 7 days for astrocyte cultures, the
dishes containing confluent mixed glia were shaken to remove microglia, the
supernatant recovered for culture of microglia, and the enriched astrocytes were
disrupted with trypsin, and 2 x 105 cells were plated onto poly-l-lysine-pre-coated
24-well tissue culture dishes. Astrocytes were grown for an additional 7 days at
which time the cultures were confluent and underwent treatment. Microglia were
isolated by differential adherence to plastic as described (Gottschall et al. 1995).
On the day of the experiment for astrocytes and microglia, cells were washed
twice with Hank’s balanced salt solution, and treatments were added to the cells
in 0.5ml of serum-free Opti-Mem medium containing 1% antibiotic-antimycotic
solution and the cells incubated for 72 h. At this time, the morphology of the
astrocytes appeared as a cobblestone-like monolayer with fibrous, processbearing phase dark cells scattered on top. More than 99% of these cells were
immunoreactive with anti-glial fibrillary acidic protein (Gottschall and Yu 1995).
At the end of 72 h, medium was collected and astrocytes or microglia were lysed
with cold extraction buffer (20mM Tris-HCl, 5mM EDTA, 1% Triton X-100,
pH=7.4, with protease inhibitor cocktail, set III (Calbiochem, La Jolla, CA) added
at a dilution of 1:100) on ice. The medium and cell lysates were stored at -80°C
until analysis by Western blot.
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Neurons were derived from embryonic day 18 cerebral cortices, cultured
and plated as described except that the cultures (2.5 x 105 cells in 12-well culture
well) were incubated in serum-containing DMEM overnight after plating and the
next day the medium was changed to Neurobasal containing B27 supplement,
0.5 mM Glutamax-I (Invitrogen, Carlsbad, CA) and 0.25 µM glutamate. The
medium was not changed for 14 days, and at the end of this time, the medium
and lysate was collected as described above for astrocytes.

Generation of anti-Peptide Antibodies
Two antibodies used in this study were custom generated by SigmaGenosys (The Woodlands, TX). Amino acid sequences were chosen and
submitted to Sigma-Genosys for peptide synthesis. The peptide was coupled to
keyhole limpet hemocyanin (KLH), and rabbits were inoculated with the
conjugate. Rabbit serum was collected by Sigma-Genosys and the antibody was
affinity purified using solid phase support coupled to the peptide in our laboratory.
The eluate from the column was dialyzed overnight, and the purified antibody
was characterized with Western blot and peptide blocking experiments to ensure
specificity. The anti-EAVESE antibody was generated with the peptide
CGGGQEAVESE, which corresponds to the neoepitope, C-terminus of the Nterminal brevican fragment (rat) generated by cleavage with ADAMTS at 395Glu Ser396 (Matthews et al. 2000). The anti-ADAMTS4 antibody was generated with
the peptide CAPLHLPVTFPGKDYDADRQ, which corresponds to a sequence in
the disintegrin-like domain of rat (and mouse) ADAMTS4.
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Immunoblotting
Culture medium and cell lysates were subjected to SDS-PAGE, followed
by electrophoretic transfer onto "Immobilon" polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA) using standard conditions. Before adding
cell lysates to the gel, protein concentration was measured and equal amounts of
protein were applied to the gel: 14µg for the anti-brevican and anti-EAVESE gels
and 22µg for the anti-ADAMTS4 gels. In the conditioned medium, the presence
of interfering substances prevented protein measurement, and thus equal
volumes of unconcentrated medium underwent SDS-PAGE and subsequent
blotting for the medium lanes of the characterization experiments and the TGFß
treatments. To ensure equal protein loading for the experiments where medium
was used, the membranes were stained with Coomassie blue, and the bands
visualized to confirm equal density of color. The membranes were probed with
several antibodies against ECM proteins and ADAMTS4. Mouse anti-brevican
(BD Biosciences, San Jose, CA) was used at a dilution of 1:1000, rabbit antiADAMTS4 antibody at 1:1000 and rabbit anti-EAVESE antibody at a dilution of
1:100. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and
HRP-conjugated goat anti-rabbit IgG secondary antibodies (Chemicon,
Temecula, CA) were used at a dilution of 1:1000. Blots were developed with
"SuperSignal" West Pico Chemiluminescent substrate (Pierce, Rockford, IL), and
chemiluminescent signal was detected on photographic film (Pierce, Rockford,
IL).
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Data Analysis
Optical density (OD) of specific signals on Western blot films was obtained
using a Bio-Rad model GS-670 Imaging Densitometer (Hercules, CA). Percent
of control was calculated by dividing the mean volume OD of the treatment group
by the mean volume OD of the control group (the mean of two controls per
experiment). Differences within an experiment were detected using ANOVA and
pairwise comparisons were made with Fisher's protected LSD (SuperANOVA
version 1.11, Abacus Concepts Inc., Berkely, CA). p < 0.05 was considered a
significant difference between two groups. The treatment experiments were
repeated three times, and the TGFβ dose-response experiments were repeated
four times. All figures show the mean of the experimental replicates as a
percent of the control level in each individual experiment.

Results
Presence of Brevican and ADAMTS4 in Enriched Astrocytes, Neurons and
Microglia
The isoforms of brevican secreted from enriched cultures of astrocytes,
neurons and microglia were examined utilizing Western blot. In astrocyte and
neuronal cultures, the full length 145 kD brevican core protein was found in
conditioned medium (Fig. 3, top panel; Fig. 2B), yet the presence of core protein
that contained CS chains, the predominant form found in adult rat brain tissue
(Fig. 3, top panel, Fig. 2A), was highly variable and appeared in the medium in
some cultures yet was absent in others (Fig. 3, lane NM top panel, higher, > 145
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kD molecular weight and observed as a smear; Fig. 2A). Relative to extracts of
adult rat brain, little CS containing brevican is present in astrocyte cultures (Fig.
3). In lysates derived from astrocytes and neuronal cultures, the 145 kD core
protein was present along with lower molecular weight isoforms that possibly
represent the underglycosylated form of brevican (Viapiano et al. 2003) or
brevican tethered to the membrane via a glycosylphosphatidylinositol (GPI)anchor (Seidenbecher et al. 1995) (Fig 3, top panel). Since samples for these
blots were whole cell lysates, it is unclear whether this "underglycosylated" form
is extracellular brevican that is cell-associated or whether it is intracellular and is
simply being processed in the secretory pathway. The 55 kD N-terminal
proteolytic cleavage fragment, thought to include products of both ADAMTS and
MMP cleavage, was found exclusively in astrocyte and neuronal conditioned
medium (the immunoreactivity in the neuronal medium lane above this band is
cross-reactivity of the antibody with B-27 supplement required for medium in
neuronal culture). The presence of these specific isoforms was confirmed with
their detection in extract from adult rat hippocampal tissue (Fig. 3 top panel, lane
RT). Likewise, the ADAMTS-derived cleavage fragment of brevican, EAVESE,
was found in astrocyte and neuronal medium, but was absent in lysate (Fig. 3,
middle panel; Fig. 2C). Microglia showed a different pattern of expression of
brevican and ADAMTS4 compared to neurons and astrocytes. Brevican or its
processed fragments were not found in microglial medium or lysate. The major
isoform of the ADAMTS4 protease is a 53 kD, N- and C-terminally truncated
protein. Interestingly, the activated isoform of ADAMTS4 (53 kD) was detected in
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the cell lysate of microglia, neurons and astrocytes, but was absent from all
medium (Fig. 3, bottom panel). The 53kD isoform of ADAMTS4 was much less
abundant in microglia, yet the 68kD, N-terminally (only) truncated form was
present, in addition, to a 32 kD isoform that was also found in human
recombinant ADAMTS4 (Fig. 3, bottom panel).

Figure 3. Brevican, ADAMTS-cleaved brevican and ADAMTS4 expression in
neural cultures.
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Figure 3. Brevican, ADAMTS-cleaved brevican and ADAMTS4 expression in
neural cultures. Brevican, ADAMTS-cleaved brevican (anti-EAVESE) and
ADAMTS-4 (top, middle and bottom panels, respectively) were detected by
immunoblot in cultures of neurons, astrocytes and microglia. Neuronal medium
and cell lysate (NM and NL), astrocyte medium and cell lysate (AM, AL) and
microglia medium and cell lysate (MM, ML) were examined. Extract from adult
rat hippocampal tissue prepared under the same conditions (RT) was the internal
brevican positive control sample whereas human recombinant ADAMTS4 (HR)
was utilized as a control for the ADAMTS4 immunoblot. Intact core brevican was
detected in neurons and astrocytes, but microglia apparently failed to express the
protein. The 55 kD (top panel) and ADAMTS-derived cleavage fragments
(middle panel) were detected in neuronal and astrocyte medium only. An
activated 53 kD isoform of ADAMTS4 was detected in the cell lysate of all three
cell types, but was not secreted into the medium, however, microglia processed
the protease differently from cultures of enriched neurons and astrocytes (bottom
panel).

Treatment with Cytokines in Astrocyte Culture
In an effort to identify factors that regulate brevican secretion and
cleavage, cultures of astrocytes were treated with phorbol myristate acetate
(PMA) (100 nM), VEGF (25 ng/ 0.5 ml), TGFβ (25 ng/ 0.5 ml), and IL-1β (200 ng/
0.5 ml) and the core protein and cleaved fragments of brevican were quantitated
using densitometry of the immunoreactive bands on Western blot (Fig. 4). TGFβ,
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but not other factors, significantly enhanced brevican levels (more than 12-fold)
found in conditioned medium of astrocyte cultures (Fig. 4, upper and middle left
panels, p <0.05). This effect was dose-related (3.12, 6.25, 12.5 and 25 ng/ 0.5
ml) with a minimal effective dose of 6.25 ng/ml TGFβ (Fig. 4, upper and middle
right panels, p < 0.05). However, in spite of the marked elevation in intact
brevican in response to TGFβ, the cleaved N-terminal fragment (55 kD) was not
significantly affected by treatment with any of the cytokines (Fig. 4, bottom
panels). Films with shorter exposures and less dense bands were used to
quantitate the optical density of the 55 kD bands (not shown). In addition, there
was a trend for decreased immunoreactivity of the ADAMTS-derived, 55 kD, Nterminal fragment in response to TGFβ (Fig. 5). In particular experiments, this
trend appeared to be dose-related (Fig. 5, upper right panel).
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Figure 4. Levels of intact brevican (145kD) and the N-terminal total cleavage
product of brevican (55 kD) in medium from cytokine-treated primary astrocyte
cultures. (Upper panels) Shown are representative blots of astrocyte medium
from cultures treated with cytokines (left) or increasing doses of TGFβ (right) and
probed with anti-brevican. (Middle panels) Quantification of levels of full-length
brevican when treated with PMA, VEGF, TGFβ and IL-1β (left) or increasing
doses of TGFβ (right), demonstrating a significant increase in full length brevican
after TGFβ treatment. (Lower panels) Quantification of levels of 55 kD brevican
fragment in response to the same treatments as the middle panels.
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Figure 5. Levels of ADAMTS cleaved brevican (55kD) in cytokine treated
astrocyte cultures. (Upper panels) ADAMTS cleaved brevican immunoreactivity
(as measured by anti-EAVESE) in astrocyte culture medium when treated with
cytokines (left panels), or increasing doses of TGFβ (right panels). No significant
change in the fragment was detected, however, a trend for a decrease in the
level of the fragment was observed.

Since levels of the ADAMTS-derived fragment of brevican either were not
changed in the face of large increases in core brevican or were actually
decreased in response to TGFβ, it was of interest to determine whether this
cytokine influenced the expression of the most abundant ADAMTS in the nervous
system, ADAMTS4. Neither TGFβ nor any of the other cytokines tested altered
the levels of ADAMTS4 protein that were found in astrocyte cell lysate (Fig 6).
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However, it may be that activity, rather than expression of the active protease
was changed, and thus, a rather semi-quantitative measure of ADAMTS activity
is the ratio of the content of the ADAMTS-derived fragment and the content of
intact core brevican. Interestingly, this ratio was markedly diminished after
treatment with TGFβ (Fig. 7, upper panel), an effect that was dose-dependent
(Fig. 7, lower panel).

Figure 6. ADAMTS-4 protein levels in response to cytokine treatment. (Upper
panels) ADAMTS-4 immunoreactivity in astrocyte cell lysate after PMA, VEGF,
TGFβ or IL-1β treatment (left) or increasing doses of TGFβ (right). (Lower
panels) There were no significant changes in ADAMTS-4 protein levels when
treated with cytokines (left) or increasing doses of TGFβ (right).
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Figure 7. Apparent ADAMTS activity in cytokine treated astrocyte cultures.
ADAMTS activity is indirectly measured by examining the ratio of ADAMTScleaved versus full length brevican. (Upper panel) ADAMTS activity in cytokine
treated astrocytes, demonstrating the marked reduction occurring with TGFβ
treatment, but not with other treatments. (Lower panel) Dose dependent
decrease in activity in response to increasing doses of TGFβ.

Discussion
Astrocytes are predominant in the production of many ECM proteins in the
nervous system. Astrocytes contribute to the formation of the basal lamina of the
cerebrovasculature, and are a major cell type responsible for the production of
ECM components that constitute perineuronal nets and the matrix of the neuropil.
One purpose of this study was to characterize the brevican-containing matrix
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present on astrocyte monolayers, since the ultimate intention is to use these
astrocytes as a substrate for growth and maturation of neurons. We have found
that astrocytes and neurons in culture synthesize and secrete the 145 kD intact
brevican core protein, a proportion of which is found in the medium and the
remainder is associated with the cell lysate fraction. It is not clear at this point
whether core brevican in the lysate is actually found extracellularly and cellassociated or whether it is intracellular, located in the secretory pathway. Two
additional isoforms were detected and found only in the lysate fraction. These
may be the underglycosylated and/or GPI-linked isoforms (Viapiano et al. 2003)
(Seidenbecher et al. 1995). Both these forms were found in lysate from primary
cultures of rat cortical neurons as well. Brevican has been identified in tissue
culture previously as one study demonstrated the presence of brevican mRNA in
cultures of cerebellar astrocytes, although the transcript was absent in rat
cerebral cortical neurons in culture (Yamada et al., 1994). More recently
however, brevican protein was detected in cultures of cerebral cortical neurons
associated with synaptic proteins (Seidenbecher et al., 2002). Interestingly, in
this study, only a small fraction of CS-bearing brevican protein was secreted from
either astrocytes or neurons, which contrasts markedly with adult rat brain tissue,
where greater than 50% of total brevican contains CS chains. (Fig. 3; Yuan et al.,
2002). It may be that the cells that express glycosyl transferases necessary for
adding the CS chains to brevican require further maturation, or that the factors
required for this maturation are produced only in mixed cultures.
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Although both MMPs and the ADAMTSs are capable of cleaving brevican
(and lecticans in general) into two fragments (Nakamura et al. 2000; Westling et
al. 2002), the main protease responsible for the extracellular processing of
brevican in vivo appears to be the ADAMTSs. ADAMTS4 mRNA is expressed in
many regions of the nervous system, it is markedly up-regulated in response to
excitotoxic injury (Yuan et al. 2002) and may be a major protease involved in
clipping the lecticans. In primary cultures of rat astrocytes, the N-terminal
cleavage fragment containing the G1 globular domain of brevican, whether the
total G1 fragment or the ADAMTS-specific fragment, were found only in medium
and not in the lysate fraction. Since this N-terminal region contains a
hyaluronan-binding domain, it suggests that hyaluronan was not part of any
pericellular matrix that was assembled in these cultures. In addition, since a
portion of intact brevican was associated with the cell surface, it may be the
brevican was bound via the C-terminal domain, possibly via binding to tenascin-R
(Aspberg et al. 1997; Hagihara et al. 1999). ADAMTSs are well known to be
bound to the pericellular region in a variety of cell types in vitro (Kuno and
Matsushima 1998), and immunoreactivity for ADAMTS4 in this study was absent
from the medium but found at clearly detectable levels in the cell lysate fraction
of astrocytes, neurons and microglia.
There are a host of ECM proteins, including the aggregating PGs,
aggrecan (Bassols and Massague 1988), versican (Stokes et al. 2001) and
neurocan (Asher et al. 2000), whose synthesis and secretion is induced by
TGFβ, so it is not surprising that we observed a marked increase in the levels of
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brevican in the medium of astrocytes in response to TGFβ. Whereas TGFβ is
protective and trophic in several systems and models of injury (Brandes et al.
1991), others have demonstrated in particular that TGFβ was destructive toward
cartilage and increased the synthesis and release of ADAMTS4, but not
ADAMTS5, in fibroblast-like synoviocytes and human chondrocytes (Yamanishi
et al. 2002; Moulharat et al. 2004). In addition, infusing decorin, an inhibitor of
TGFβ, into damaged spinal cord led to an 80% reduction in proteoglycan
expression (Davies et al 2004) and improved the outcome of the injury. In this
study, TGFβ was a potent inducer of brevican production in the culture medium
that may be the result of stimulated gene expression. However, even in the
presence of this marked elevation of the level of intact brevican, there was a
trend for a decline in the production of the N-terminal proteolytic fragment after
TGFβ. Thus, when using the ratio of the ADAMTS-derived fragment of brevican
and intact brevican as an estimate of ADAMTS activity, there was a dramatic
decline in the apparent ADAMTS activity after TGFβ treatment of cultured
astrocytes. When measuring ADAMTS4 protein level, though, by Western blot,
the levels were not changed. However, several mechanisms might explain the
decline in ADAMTS activity without a change in protein after TGFβ. First, TGFβ
has been shown to be a potent stimulator of tissue inhibitor of metalloproteinase3 (TIMP-3) production, and TIMP-3 is a potent endogenous inhibitor of ADAMTS
activity. Other TIMPs are either less potent or not effective in inhibiting ADAMTS
activity (Kashiwagi et al. 2001). Second, it may be that TGFβ altered the
processing of ADAMTS4 by inhibiting a membrane type protease that converts it
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to its lower molecular weight active form (Gao et al. 2004), although this
alteration in processing should have been recognized by observing a higher
molecular weight isoform of ADAMTS4 on Western blot. Third, TGFβ may be
inducing proteases or other factors that could sequester or degrade the fragment,
such as carboxypeptidases that diminish its detection. Finally, one cannot rule
out the possibility that ADAMTS4 (or the sum of all active ADAMTSs) is saturated
by its brevican substrate and increases in substrate concentration do not result in
elevated product (fragment) simply because the protease was acting maximally
at the lower concentration of substrate.
Nonetheless, these results demonstrate that brevican is secreted by
astrocytes and neurons in culture, that TGFβ is a potent stimulator of brevican in
astrocytes, and that TGFβ also attenuates ADAMTS cleavage of brevican.
These findings suggest that TGFβ, which is often released in response to various
injuries, may be non-permissive toward neural plasticity and regeneration. Since
intact brevican may stabilize synaptic networks (Hockfield et al. 1990), and
because cleavage of brevican may loosen aggregates of ECM in the brain and
produce favorable conditions for morphological plasticity (Yamaguchi 2000; Yuan
et al 2002), it may be that TGFβ stabilizes these networks by diminishing the
cleavage of brevican. The mechanism of such a response remains to be
elucidated.
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Chapter 2: ADAMTSs (a disintegrin and metalloproteinase with thrombospondin
motifs) Enhance Neurite Outgrowth through a Non-Proteolytic Mechanism
Mediated by Extracellular Signal-Related Kinase1/2

Abstract
Aggregating proteoglycans (PG) bearing chondroitin sulfate (CS) side
chains are well-known inhibitors of neural plasticity and associate with
hyaluronan and tenascin-R to form a complex of extracellular matrix (ECM) in the
central nervous system (CNS). Chondroitinase treatment depletes PGs of their
CS side chains and enhances neural plasticity including neurite extension. Little
is known about whether proteolytic cleavage of the core protein affects neural
plasticity. Several members of the ADAMTS (a disintegrin and metalloproteinase
with thrombospondin motifs) family of metalloproteinases are glutamylendopeptidases that cleave aggregating PGs. The purpose of this study was to
determine whether cleavage of aggregating PGs, especially brevican, by the
ADAMTSs influences neurite outgrowth in cultured neurons. Transfection of rat
neurons with ADAMTS4 cDNA induced longer neurites, whether the neurons
were grown on a monolayer of astrocytes that secrete inhibitory PGs or on
laminin/poly-l-lysine substrate alone. Even more surprising, the increase in
process extension was also observed when neurons were transfected with an
36

expression vector construct coding for a proteolytically inactive, point mutant of
ADAMTS4. Addition of recombinant ADAMTS4 or ADAMTS5 protein to
immature neuronal cultures similarly enhanced neurite extension. Increases in
the abundance of proteins phosphorylated on tyrosine residues and more
specifically, the amount of phosphorylated extracellular signal-related kinase
(ERK)1/2 (MAP kinase 42/44) immunoreactivity were detected shortly after the
addition of recombinant ADAMTS4 to neurons. Furthermore, ADAMTS-induced
increases in neurite outgrowth were diminished by treatment with selective MAP
kinase inhibitors. These results demonstrate that ADAMTS4 enhances neurite
outgrowth and does so likely via induction of signaling at the cell surface and
activation of the MAP kinase cascade, an action that does not require the
proteolysis by ADAMTS4.

Introduction
Injury to the central nervous system (CNS) is often debilitating and is
compounded by little hope of recovery owing to the fact that once neural
networks in the CNS are severed, they are difficult to re-establish.
Predominantly, this is because the properties of myelin-associated proteins and
other proteins that compose a glial scar impede the growth of axons toward their
target. The glial scar is an accumulation of reactive astrocytes and extracellular
matrix (ECM) molecules such as chondroitin sulfate (CS)-substituted PGs,
keratin and tenascin that inhibit the re-growth of axons and the migration of
particular cell types into the damaged region of the brain (Davies et al., 1997;
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Davies et al., 1999) (Laywell et al., 1992) (McKeon et al., 1991). Indeed, the CS
side chains of PG molecules are well-known to inhibit neurite outgrowth under a
variety of in vitro and in vivo conditions (Silver and Miller, 2004; Carulli et al.,
2005).
The family of hyaluronic acid-binding PGs with CS side chains that
regulate cell adhesion, migration and neurite outgrowth in the CNS are termed,
lecticans, and include aggrecan, brevican, neurocan and versican. Large,
sulfated, highly negatively-charged CS chains are covalently bound to the central
domain of lecticans and discourage growth cone motility and neurite elongation,
however, when these glycosaminoglycan polymers are removed from the core
proteins by chondroitinase treatment (Pizzorusso et al., 2002), a significant
degree of inhibition is retained by versican (Schmalfeldt et al., 2000), but not by
brevican (Miura et al., 2001). The enduring biological action may be inherent to
the core PG protein itself or it may result from interactions with other ECM
molecules such as hyaluronan or tenascin-R. Intermolecular interactions among
lecticans, hyaluronan and tenascin form a mesh-like lattice in the matrix of the
CNS that could inhibit neural plasticity (Fig. 8, A). Thus, to facilitate plasticity,
there should be a means to relieve the inhibition afforded by the PG. The
absence of an endogenous chondroitinase to remove CS chains is a major
limiting factor, so taking advantage of a mechanism that occurs in vivo may be a
more feasible way to re-establish plasticity in the brain. One such possibility
would be via increased expression and activation of endogenous proteases that
cleave the PG, a mechanism that would loosen the association and interaction
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among the matrix components that inhibit plasticity, and allow for enhanced
neural growth (Fig 8, B).

Figure 8. Lectican-tenascin-hyaluronan matrix complex in the CNS and lectican
cleavage by ADAMTSs.
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Figure 8. Lectican-tenascin-hyaluronan matrix complex in the CNS and lectican
cleavage by ADAMTSs. (A), Intact complexes of extracellular matrix form an
inhibitory boundary toward neurite outgrowth by hyaluronic acid binding to the Nterminus, tandem repeats of the lecticans and tenascin binding to the C-terminus
of the lecticans. (B), Cleavage of lectican by an ADAMTS loosens the stable,
matrix network, increasing fluidity and potentially allowing for increased plasticity.
(C, D), Cleavage of the lectican, brevican, by human recombinant ADAMTSs.

Proteoglycans were purified from rat brain extracts contained in fractions
eluted from a DEAE column with 1 M NaCl. Lectican-containing fractions were
incubated with active ADAMTSs, or heat-inactivated protease (Inactive),
subjected to SDS-PAGE, and probed with anti-brevican antibody (C) to reveal
holoproteins and the N-terminal cleavage product or with anti-EAVESE antibody
to selectively reveal the N-terminal fragment that contains the EAVEAE
neoepitope exposed by ADAMTS-cleavage of brevican (D). "Control" lane
shows brevican immunoreactivity as a smear at a molecular weight of >145 kD.
Samples containing inactive ADAMTS show little cleavage, whereas brevican
substrate incubated with human recombinant ADAMTSs 1, 4 and 5 (25 nM) for 3
hours reveal an abundance of the 55 kD, N-terminal cleavage fragment (C) that
is observed when probed with antibody selective for the ADAMTS-cleaved
fragment (D).

40

The ADAMTSs (a disintegrin and metalloproteinase with thrombospondin
motifs) are multi-domain, metalloproteinases that have notable roles in
angiogenesis, coagulation, collagen processing, cell migration and arthritis.
Several of the ADAMTSs are glutamyl-endopeptidases that cleave lecticans.
These secreted proteases share similar functional domains, including a prodomain, metalloproteinase, disintegrin-like, cysteine-rich and spacer domains (for
review, see (Apte, 2004)). Activation of the pro-protease likely occurs by furinmediated cleavage of the pro-domain at the N-terminus, and further C-terminal
truncations are necessary to fully activate the enzyme (Wang et al., 2004) (Gao
et al., 2004a) (Kuno et al., 1999). The interaction of the ADAMTS domains with
their substrates is complex and may involve binding via the thrombospondin type
1 motif and/or sequences in the C-terminal spacer or cysteine-rich region of the
molecule (Kuno and Matsushima, 1998; Tortorella et al., 2000; Flannery et al.,
2002; Kashiwagi et al., 2004).
ADAMTSs, especially ADAMTS 1, 4, 5, and 9, are expressed in brain
(Hurskainen et al., 1999; Yuan et al., 2002; Jungers et al., 2005) (our
unpublished observations), and it is interesting that each of these proteases is
active in cleaving PGs. Several of the ADAMTSs have been shown to be
elevated in human neurodegenerative disease and animal models of brain injury.
ADAMTS1, but not ADAMTS5, appears to be up-regulated in Down syndrome,
Pick’s disease and Alzheimer’s disease (Miguel et al., 2005). The expression of
ADAMTS4 and ADAMTS1 mRNA was markedly elevated in the hippocampus of
rats in response to kainate-induced excitotoxic lesion (Yuan et al., 2002), and
41

ADAMTS1 was increased in the spinal cord of rodents having undergone
axotomy (Sasaki et al., 2001), indicating that these proteases may be increased
in response to injury or during an inflammatory response.
Anecdotal, but growing evidence has supported the notion that
metalloprotease activity is important in mechanisms of neural plasticity. Nerve
growth factor treatment of PC-12 cells results in MMP-3 expression (Machida et
al., 1989; Fillmore et al., 1992), and MMP-3 is essential in promoting PC12 cell
growth cone invasiveness through an artificial basal lamina (Nordstrom et al.,
1995). More recently, excitotoxic lesion in the brain was shown to result in the
expression of MMP-9 in the hippocampus (Zhang et al., 1998; Szklarczyk et al.,
2002) and neuritic sprouting observed in the dentate gyrus after a lesion of
entorhinal cortex was blocked by administration of a broad spectrum MMP
inhibitor (Reeves et al., 2003). These actions certainly point toward a role for the
matrix-degrading metalloproteinases in neural plasticity. We recently
demonstrated that active ADAMTSs which cleave the lectican, brevican, are
elevated in the dentate gyrus terminal zone during the period of neuritic sprouting
after entorhinal cortex lesion (Mayer et al., 2005). Taken together, these studies
support the hypothesis that remodeling of ECM may be an important component
in processes of neural and synaptic plasticity. Thus, the purpose of this study
was to more directly test the hypothesis that lectican-degrading activity may
promote neurite outgrowth over an ECM that contains inhibitory PGs. We grew
primary cultured neurons that were either secreting ADAMTS4 via a transfected
expression vector or were exposed to ADAMTSs by direct addition of
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recombinant protein to the media. In some of these experiments, neurons were
grown on an astrocyte monolayer that had previously been shown to deposit
brevican in the ECM (Hamel et al., 2005; John et al., 2006). Surprisingly, our
results show that ADAMTS4, and other ADAMTSs, promote neurite outgrowth in
primary cultured embryonic neurons via a mechanism that is independent of its
proteolytic activity. In addition, intracellular signaling, appropriate for neurite
outgrowth, is induced in ADAMTS-treated neurons.

Materials and Methods
PG degradation assay
Highly negatively charged molecules, including PGs, present in whole rat
brain extracts were bound and eluted from a DEAE matrix as described (Yamada
et al., 1994). Briefly, rat brain tissue (1g) was placed in 10 ml, ice cold, 4 mM
HEPES pH 8.0, 0.15 mM NaCl, 0.1% Triton-X-100 containing 2 mM 1,10
phenanthroline (Sigma, St. Louis) and protease inhibitor cocktail (set III,
Calbiochem, San Diego). The tissue was disrupted in a teflon-glass
homogenizer and the whole extract centrifuged at 30,000 x g for 30 min at 4˚C.
The supernatant was removed, diluted 1:1 with 50 mM Tris-HCl, 0.15 M NaCl,
0.1% Triton-X-100, and passed over a DEAE column pre-equilibrated with the
same buffer at a flow rate of less than 0.5 ml per minute. The flow through was
collected, passed over the column again, and bound proteins were eluted with 5
column volumes of consecutive buffers containing 50 mM Tris-HCl pH 8.2, 0.15
M NaCl, 0.1% Triton-X-100, then 50 mM Tris-HCl pH 8.2, 0.25 M NaCl, 6 M urea,
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0.1% Triton-X-100, and fractions containing PGs were eluted with 50 mM TrisHCl pH 8.2, 1.0 M NaCl. PG-containing fractions were dialyzed against water for
24 h in SpectraPor 6000-8000MWCO (Millipore, Billerica, MA) membrane, the
samples concentrated on a speed-vac and aliquoted. Total protein was
measured in the samples and it was 1.3 µg/µl. DEAE-purified PG samples were
incubated with 25 nM recombinant ADAMTS1 (Chemicon), ADAMTS4 or
ADAMTS5 (expressed at Roche Biosciences, Palo Alto) (diluted in 10 mM TrisHCl, 0.15 M NaCl, and 10mM CaCl2) for three hours at 37˚C. ADAMTS4 and
ADAMTS5 were inactivated by heating to 95˚C for thirty minutes and were
included as controls. After a three hour incubation period, beta-mercaptoethanolcontaining SDS-PAGE sample buffer was added to the samples, the samples
were heated at 95˚C for 4 minutes, and subjected to SDS-PAGE and Western
blotting. Membranes were probed with mouse anti-brevican (BD Biosciences,
San Jose) at 1:1000 and anti-EAVESE (Hamel et al., 2005) at 1:100, and primary
antibody detected with anti-mouse or anti-rabbit IgG conjugated to horse-radish
peroxidase (Chemicon, Temecula, CA), and signal detected using SuperSignal
chemilluminscence substrate (Pierce, Rockford, IL).

Primary cell cultures
Primary cultures of astrocytes were prepared from whole brain (minus
cerebellum) of postnatal day 1-3 Sprague-Dawley (SD) (Harlan, Indianapolis) rat
pups in Dulbecco's Modified Eagles Medium containing 10% horse serum and
2.5% fetal calf serum as described (Hamel et al., 2005). Astrocytes were grown
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in 100mm tissue culture dishes pre-coated with 100 µg/ml poly-L-lysine for seven
days until confluent. The cells were disrupted with trypsin and plated at 1x106
cells on 22 mm glass coverslips (Fisher Scientific, Pittsburgh) pre-coated with
500µg/ml poly-l-lysine (Sigma). Seven days later, the astrocytes had formed a
confluent monolayer and at this time, the cells were used as a neuronal growth
substrate. Freshly prepared, trypsinized cells from cerebral cortex of embryonic
day 18 SD pups (Hamel et al., 2005) were transfected with ADAMTS4
expression vector or empty control vector and 1x106 cells were plated either
directly on the confluent astrocyte monolayer or onto glass coverslips pre-coated
with 500 µg/ml poly-L-lysine and 25 µg/ml mouse laminin (Invitrogen, Carlsbad).
Twenty-four hours after plating the neurons, plating medium that consisted of
Dulbecco's Modified Eagles Medium plus 10% fetal calf serum was replaced with
Neurobasal serum-free medium (Invitrogen) containing B-27 defined supplement
(Invitrogen), 0.5mM Glutamax II (Invitrogen-Gibco, Carlsbad) and 25µM
glutamate, and containing 1% antibiotic/antimycotic (Invitrogen-Gibco). Neurons
plated either on an astrocyte monolayer or in the absence of the monolayer were
cultured for seven days.

Transfection by electroporation
For the experiments described above, plasmid expression constructs of
ADAMTS4 were made for transfection into primary rat cells trypsinized from
cerebral cortex. A cDNA for ADAMTS4 (Gao et al., 2002), and an inactive point
mutant of ADAMTS4 362 (E→Q) (Gao et al., 2004a) that were inserted into
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pcDNA (Invitrogen), were restricted with Xba I and Kpn I (Promega, Madison),
the ADAMTS4 (or mutant) fragment purified from an agarose gel and ligated into
linearized pCMS plasmid, a dual promoter vector that expresses enhanced green
fluorescent protein (EGFP) driven by SV40 (Clontech, Mountain View, CA). After
cells from cerebral cortex of E18 SD pups were isolated, 5x106 cells were
centrifuged and resuspended in 100µl rat nucleofector solution (Amaxa
Biosystems, Gaithersburg, MD). The cells were transferred to a cuvette and
pCMS, pCMS-ADAMTS4 or pCMS-ADAMTS4 mutant were added and the
cuvette subjected to electric current using the Nucleofector electroporator
(Amaxa Biosystems) with either the O-03 or G-13 time and current preprogrammed by the manufacturer. Immediately after transfection, 500µl of prewarmed, 37°C Dulbecco's Modified Eagles Medium with 10% fetal calf serum
was added to the cell suspension, and the cells were transferred to a sterile
microcentrifuge tube until plating. The transfected neurons were plated on glass
coverslips pre-coated with the laminin/poly-L-lysine substrate or they were
allowed to adhere directly to a previously cultured, live astrocyte monolayer.
Neurons were allowed to extend neurites for seven days. After this time, cells
were washed one time in PBS, fixed in 4% room temperature paraformaldehyde
for twenty minutes, and washed an additional three times with PBS. Transfected
cells were visualized under epifluorescence using a Zeiss Axioskop microscope
interfaced with an Axiocam (Zeiss, Thornwood, NY) digital camera and images
were obtained with Openlab software (version 3.1.4, Improvision, Lexington,
MA). For all images, the brightness and contrast were adjusted equally and
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consistently for images within a single experiment, and converted to grayscale
using Adobe Photoshop (Version 8.0, San Jose).

Data collection and statistical analysis – transfection experiments
ImageJ software (Version 1.33u, NIH, Bethesda) was utilized to manually
trace primary and secondary neurites to determine overall mean length of
neurites per neuron and mean length of the longest neurite for each neuron. A
primary neurite was defined as a neurite that sprouted directly from the soma and
was at least two times the diameter of the cell body. A secondary neurite was
defined as any neurite that branched from a primary neurite. Numbers of primary
and secondary neurites were also recorded. The mean longest neurite was
calculated by averaging the values of the longest neurite for each neuron
measured, whereas the overall mean length of primary neurites was calculated
by averaging values of every primary neurite measured. Secondary neurites
were analyzed similarly. Means of experimental groups were statistically
compared using ANOVA and pair-wise comparisons were made with TukeyKramer post-hoc test (SuperAnova, v 1.11, Abacus Concepts, Berkeley). A
p<0.05 was considered a significant difference between groups. Separate litters
of rat pups were used to obtain cells for each of the three experiments.

ADAMTS4 protein treatment
Neurons grown at 2.5x105 cells per well were cultured on 22 mm glass
coverslips for six days and treated at 2 and 5 days in vitro with human
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recombinant ADAMTS4 orADAMTS5. Purified recombinant ADAMTS4 and 5
were provided by Roche Biosciences. Recombinant protein was diluted in
Neurobasal medium plus 0.1% bovine serum albumin (BSA) and syringe filtered
to sterilize. BSA was added to prevent adherence of the recombinant protein to
the filter. Each of the ADAMTS protein preparations contained low, but
detectable levels of endotoxin using the LAL assay (Cambrex, Walkersville, MD)
that were comparable to the BSA controls. Control wells received a matched
volume of filtered Neurobasal medium plus 1% BSA. Untreated controls were
also measured in some experiments. At six days in vitro, neurons were fixed with
4% paraformaldehyde and processed for immunohistochemistry.

Immunohistochemistry
Neuronal cultures fixed as described above were incubated for one hour in
blocking buffer containing 10% normal goat serum (NGS), 0.3% triton-X-100 and
1M lysine in PBS at room temperature. Cells were incubated overnight at 4˚C in
dilution buffer (PBS, 10% NGS, 0.3%Triton-X-100) containing mouse antimicrotubule associated protein-2 (Chemicon) diluted to 1:200. The cells were
washed three times in PBS and Alexa Fluor goat anti-mouse IgG fluorescent
secondary antibody (Invitrogen) was incubated at a concentration of 1:500 for 1 h
and the coverslips washed three times in PBS. Next, the coverslips were
incubated with a fluorescent-tagged, actin binding protein, Alexa-Fluor 488
phalloidin (Molecular Probes/Invitrogen), at a dilution of 1:500 in 2% NGS and
0.3%Triton-X-100 in PBS for 45 minutes at room temperature, followed by an
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additional three rinses in PBS. The coverslips were then mounted on slides with
Vectashield (Vector Laboratories, Burlingame, CA) fluorescent mounting medium
and the cells were visualized with epifluorescence. Neurons were photographed,
brightness and contrast of all photomicrographs were enhanced equally, and
images converted to grayscale using Adobe Photoshop.

Data collection and statistical analysis – protein treatment
Due to a higher density of neurites compared to the transfection
experiments, it was impossible to discern individual neurites to make length
measurements. Thus, neurites from a group that was blinded from the
experimenter were traced on a new layer in Adobe Photoshop. The background
layer containing the photomicrograph was deleted, leaving the tracings, and
ImageJ software was utilized to calculate the area of the image occupied by the
neurite tracings. This area was divided by the number of neurons in the field
image, generating µm2 of neurite signal per neuron. A mean was calculated for
the area occupied by neurites per neuron for several images and differences
between the means were determined by ANOVA and the Tukey-Kramer multiple
comparison test. A p < 0.05 was considered a statistically significant difference
between groups.

Phosphotyrosine and ERK1/2 analysis
Neurons were cultured for five days in vitro and treated with 50nM
ADAMTS4. At 20, 40 and 60 minutes after addition of ADAMTS4, 20mM Tris49

HCl, 5mM EDTA, 1% Triton-X-100, and protease inhibitor cocktail set III
(Calbiochem) were added to cells for fifteen minutes on ice, the extract scraped
from the dish, centrifuged and stored at -80˚ C. Neuronal lysates were subjected
to Western blot analysis on 10% Tris-glycine SDS-PAGE gels, and the proteins
were transferred onto Immobilon membranes (Millipore). Membranes were
probed with rabbit anti-ERK1/2, rabbit anti-phospho-ERK1/2 (Chemicon) and/or
mouse anti-phosphotyrosine (BD Biosciences) and the presence of primary
antibody was detected with HRP conjugated to secondary antibody as described
for anti-brevican and anti-EAVESE above. The same blots were re-probed for
phosphotyrosine and ERK analysis and densitometric measures of the
immunoreactive protein bands were obtained from the ERK blots and the ratio of
activated phospho-ERK1/2 was calculated by dividing phospho-ERK protein
band density by total ERK1/2 band density. The time at which the maximum
stimulation of ERK1/2 was observed was somewhat variable between
experiments. Thus, representative blots and representative densitometric
measures are shown in Fig. 13 and 14, with similar, but not identical, results
seen in the replicate experiments.

MAP kinase inhibition
Neurons were treated with MAP kinase inhibitors thirty minutes before the
addition of 50nM ADAMTS4 to the cultures as described above. PD98059,
(Tocris, Ellisville, MO), a selective inhibitor of activated ERK1/2, and U0126
(Tocris), an inhibitor of active and inactive ERK1/2, were added at 10, 25 and
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50µM before the addition of 50nM ADAMTS4. U0124 (Tocris), the inactive
analog of U0126, was used as a negative control at 10, 25 and 50µM as well.
Cultures were treated and incubated as described above and images of neurons
were captured, processed and examined in the same manner as in the ADAMTS
protein treatment experiments.

Results
Degradation of purified PG by recombinant ADAMTSs
To ensure that the human recombinant ADAMTS proteases used in these
experiments were effective in degrading brevican purified from rat brain, human
recombinant ADAMTS1, ADAMTS4 and ADAMTS5 were incubated with DEAEextracted PGs. Soluble homogenate of rat brain was applied to a DEAE column
and highly negatively-charged species were eluted with 1 M NaCl. These
proteins were incubated with active or heat-inactivated preparations of the
human recombinant ADAMTSs. At the end of a 3 h incubation period with 25 nM
of each recombinant ADAMTS, the samples were subjected to Western blot for
brevican. Brevican detected in DEAE-eluant in the absence of recombinant
protease was observed as a smear > 145 kD representing isoforms bearing
various numbers of CS chains (Fig. 8C, control). Incubation of DEAE eluants
with ADAMTS 1, 4 and 5 resulted in cleavage of brevican and the appearance of
a 55kD N-terminal fragment (Fig. 8C). This same 55 kD fragment was detected
when the membrane was probed with a rabbit antibody that recognizes the
ADAMTS-specific, C-terminal, neoepitope rat sequence, EAVESE, exposed on
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the N-terminal fragment of ADAMTS-cleaved brevican (Fig. 8D) (Hamel et al.,
2005). After cleavage by each protease, the abundance of intact brevican was
clearly diminished. Proteolytic activity was lost or significantly attenuated when
the ADAMTS4 or ADAMTS5 preparations were heat inactivated prior to
incubation with substrate (Fig. 8C and 8D). These results demonstrate that each
of the recombinant preparations of the ADAMTSs was proteolytically active.
Neurite extension in primary rat neurons transfected with ADAMTS4 cDNA grown
on an astrocyte monolayer
Since monolayers of rat astrocytes express brevican that remains
associated with the cell layer (Hamel et al., 2005), we were interested in
determining whether overexpression of ADAMTS4 would stimulate cleavage of
brevican and/or other PGs present in the astrocyte monolayer matrix and thus,
promote neurite outgrowth in cells expressing ADAMTS4. To accomplish this,
primary rat neurons were transfected with pCMS-EGFP vector that contained a
human ADAMTS4 cDNA insert. Other neurons were transfected with pCMSEGFP plasmid without the ADAMTS4 insert. The transfected neurons were
plated on mature astrocyte monolayers, ie. two-week old cultures of postnatal
day three astrocytes that had been sub-cultured one time. Seven days after
plating, photomicrographs of fixed cultures were imaged (Fig. 9A, 9C) and
tracings were made of neurites (Fig. 9B, 9D). Autofluorescence attributed to the
astrocyte monolayer can be seen in the photomicrographs (Fig. 9A, 9C).
Neurons transfected with ADAMTS4 cDNA more readily penetrated the astrocyte
matrix, and extended 20 – 40% longer primary and secondary neurites as
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compared to neurons transfected with empty vector (p ≤ 0.05) (Fig. 9E). There
was no statistically significant difference in the number of primary neurites
between control empty vector transfected neurons and those transfected with
pCMS-EGFP ADAMTS4 cDNA, however, the number of secondary neurites was
significantly increased in ADAMTS4-transfects (p ≤ 0.05) (Fig. 9E, bottom right
panel). Neurons from multiple coverslips taken from a single culture were utilized
in this experiment, and similar results obtained in a replicate experiment.

Figure 9. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on
astrocyte monolayers.
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Figure 9. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on
astrocyte monolayers. Primary cortical neurons transfected with empty pCMS
vector or pCMS inserted with ADAMTS4 cDNA were grown on a previously
prepared astrocyte monolayer for 7 days. Representative photomicrographs
depict neurons transfected with empty pCMS (A) or with the ADAMTS cDNA
insert (C). Photographs were taken of the fluorescing neurons and neurites were
traced as a measure of neurite outgrowth (B, pCMS; D, pCMS-ADAMTS4).
Means ± SEM of traced neurons reveal ADAMTS4 increases several parameters
of neurite outgrowth including the mean longest primary and secondary neurites,
overall mean primary and secondary neurites and number of secondary neurites
(* signifies p ≤ 0.05 compared to control pCMS vector alone). No significant
difference was observed in the mean number of primary neurites in response to
ADAMTS4 cDNA transfection (p > 0.05). A single independent neuronal culture
was utilized to measure 117 primary and 84 secondary neurites from 50 empty
pCMS-transfected neurons and 127 primary and 124 secondary neurites from 37
pCMS-ADAMTS4-transfected neurons. Similar data was obtained when the
experiment was repeated. Scale bars, 50µm.

Neurite extension in primary rat neurons transfected with ADAMTS4 cDNA grown
directly on substrate without an astrocyte monolayer
If ADAMTS4 was proteolytically degrading a substrate on the astrocyte
monolayer, releasing the neurites from exposure to the inhibitory matrix, then
neurons transfected with ADAMTS4 cDNA and neurons transfected with empty
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vector should extend neurites equally as well when grown directly on plastic, in
the absence of an astrocyte-derived ECM. To test this notion, neurons were
transfected as above, plated directly on poly-L-lysine/laminin-coated coverslips,
and allowed to extend neurites (Fig. 10). Interestingly, these sets of neurons
exhibited neurite growth behavior similar to that observed when neurons were
grown on the astrocyte monolayer. Neurons overexpressing ADAMTS4 (Fig.
10C, D) extended longer neurites as compared to control transfects (Fig. 10A, B)
when grown on the poly-L-lysine/laminin substrate. ADAMTS4 overexpression
induced significant increases in all parameters measured (Fig. 10E, p ≤ 0.05), in
this case, including the number of primary and secondary neurites. A single,
independent neuronal culture generated the neurons used in this experiment,
and similar results obtained in a replicate experiment.
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Figure 10. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on a
poly-L-lysine/laminin substrate.
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Figure 10. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on a
poly-L-lysine/laminin substrate. Primary cortical neurons transfected with empty
pCMS vector or pCMS inserted with ADAMTS4 cDNA were grown on poly-Llysine/laminin coated coverslips in the absence of an astrocyte monolayer for 7
days. Representative photomicrographs depict neurons transfected with empty
pCMS (A) or with the ADAMTS cDNA insert (C). Photographs were taken of the
fluorescing neurons and neurites were traced as a measure of neurite outgrowth
(B, pCMS; D, pCMS-ADAMTS4). Means ± SEM of traced neurons reveal
ADAMTS4 induced statistically significant (* signifies p ≤ 0.05 compared to
pCMS vector alone) increases in several parameters of neurite outgrowth
including the mean longest primary and secondary neurites, overall mean
primary and secondary neurites and the number of primary and secondary
neurites. 112 primary and 48 secondary neurites from 45 empty pCMStransfected neurons and 136 primary and 107 secondary neurites from 44
pCMS-ADAMTS4 transfected neurons derived from a single independent
neuronal culture were analyzed. Similar data was obtained when the experiment
was repeated. Scale bars, 50µm.

Effects of ADAMTS4 on neurite outgrowth are independent of proteolysis
To more directly determine whether the proteolytic action of ADAMTS4
was leading to increases in neurite outgrowth, transfection experiments were
carried out again with an experimental group that was transfected with a pCMS
construct that contained an ADAMTS4 cDNA bearing a point mutation in the
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protease (Fig. 11, inactive ADAMTS4 mutant). This cDNA encodes a protein
with a single amino acid substitution 362 (E→Q) in the catalytic domain resulting
in an inactive protease, yet it contains all other functional domains of ADAMTS4.
Quite surprisingly, neurons transfected with either active ADAMTS4 cDNA or
neurons transfected with proteolytically inactive ADAMTS4 cDNA extended
longer neurites in the absence of an astrocyte monolayer. Representative
photomicrographs show increases in neuritic growth (Fig. 11A, B: control; 11C,
D: ADAMTS4; 11E, F: inactive ADAMTS4 mutant). Transfection with either the
active or inactive ADAMTS4 construct resulted in enhanced length of the longest
primary and secondary neurites, and the mean length of all primary and
secondary neurites. (Fig. 11G). There was even a modest, but significant
increase in the mean length of primary neurites in neurons transfected with the
inactive ADAMTS4 mutant, compared to the wild-type ADAMTS4 cDNA (Fig.
11G, top middle panel). A single independent neuronal culture was used in this
experiment, and similar results obtained in a replicate experiment.
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Figure 11. An inactive mutant ADAMTS4 cDNA enhances neurite outgrowth.
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Figure 11. An inactive mutant ADAMTS4 cDNA enhances neurite outgrowth.
Primary cortical rat neurons transfected with empty pCMS vector, pCMS inserted
with ADAMTS4 cDNA, or pCMS vector inserted with an inactive mutant form of
ADAMTS4 cDNA were grown on poly-L-lysine/laminin coated coverslips in the
absence of an astrocyte monolayer for 7 days. Due to a point mutation in the
catalytic domain (362 E→Q), this ADAMTS4 protein possesses the same
structural domains as native ADAMTS4, but lacks any proteolytic capacity.
Representative photomicrographs depict pCMS (A), pCMS-ADAMTS4 (C) and
pCMS inactive ADAMTS4 mutant (E) expressing neurons. Photographs were
taken of the fluorescing neurons and neurites were traced as a measure of
neurite outgrowth (B, pCMS; D, pCMS-ADAMTS4, F, pCMS inactive ADAMTS4
mutant). Means ± SEM of traced neurons reveal ADAMTS4 and inactive
ADAMTS4 mutant induced statistically significant (* signifies p ≤ 0.05 compared
to pCMS vector alone) increases in several parameters of neurite outgrowth
including the mean longest primary and secondary neurites, overall mean
primary and secondary neurites and the number of secondary neurites. There
was an additional increase in the mean length of primary neurites of neurons
transfected with pCMS inactive ADAMTS4 mutant cDNA compared to neurons
transfected with pCMS-ADAMTS4 cDNA, (** signifies p ≤ 0.05 compared to
pCMS-ADAMTS4). No significant differences (p > 0.05) were observed in the
mean number of primary neurites in response to ADAMTS4 cDNA transfection.
A single independent neuronal culture was utilized and 288 primary and 181
secondary neurites from 111 empty pCMS-transfected neurons were examined.
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207 primary and 171 secondary neurites from 70 pCMS-ADAMTS4-transfected
neurons were measured, and 325 primary and 316 secondary neurites from 129
pCMS-inactive ADAMTS4-transfected neurons were quantified. Similar data was
obtained when the experiment was repeated. Scale bars, 50µm.

Effect of recombinant ADAMTSs on neurite outgrowth
To test the effects of ADAMTS4 protein on neurite extension and
potentially confirm the results seen with transfection, increasing concentrations of
human recombinant ADAMTS4 were added to the medium of neurons at 2 and 5
DIV and neurite length measured at 8 DIV. Neurons were also treated with
ADAMTS5 to determine whether this was an effect selective to ADAMTS4. Each
recombinant protein was diluted with BSA in culture medium and filter sterilized
prior to addition to the culture. Control wells consisted of untreated neurons and
neurons treated with filtered medium and BSA (Fig. 12B, C) to ensure that the
BSA was not affecting neurite outgrowth. At 8 DIV, neurons were
immunostained with microtubule-associated protein-2 and stained with phalloidin,
images collected, and the lengths of neurites traced. Compared to the
transfection experiments, where low numbers of neurons were visible due to low
transfection efficiency, all neurons were stained and visible with dense networks
of neurites. For quantification, all neurites were traced in an individual field, and
the "area occupied by neurite tracing" calculated. When divided by the number
of neurons in the field, it resulted in the area occupied by neurite tracing per
neuron (µm2 tracing/neuron).
61

The addition of BSA in culture medium had no significant effect on neurite
outgrowth compared to untreated cultures of neurons. When neuronal cultures
were treated with ADAMTS4, there was a dose-dependent increase in neuritic
growth, with a statistically significant increase at 10 (Fig. 12D, E) and 50nM
ADAMTS4 (Fig. 12A, F and G, p ≤ 0.05). ADAMTS5, a member of this protease
family not highly expressed in the nervous system, also significantly increased
growth of neurites compared to control cultures (Fig. 12A, H and I, p ≤ 0.05).
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Figure 12. Human recombinant ADAMTS4 induces neurite outgrowth.
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Figure 12. Human recombinant ADAMTS4 induces neurite outgrowth.
Representative photomicrographs and tracings are shown of primary cortical rat
neurons grown on poly-L-lysine/laminin and treated with ADAMTS4 at 1, 10 (D,E)
and 50nM (F,G) and ADAMTS5 at 10nM (H,I) or culture medium containing BSA
(B,C) at days 2 and 5 of culture and neurite outgrowth measured at day 6. At the
end of culture, neurons were visualized by using anti-microtubule associated
protein-2 immunocytochemistry and the Alexafluor 488-conjugated actin binding
protein, phalloidin. The photomicrographs (B,D,F,H) were converted to grayscale
and neurites traced (C,E,G,I). Data was calculated by dividing the area of the
photograph occupied by neurite signal (µm2) divided by number of neurons in the
field to generate mean ± SEM (µm2/neuron) that are shown in panel A.
Treatment with ADAMTS4 resulted in a dose-dependent increase in neurite
outgrowth (see panel A) and 10nM ADAMTS5 also significantly increased neurite
outgrowth (* p ≤ 0.05 compared to untreated or medium + BSA treated wells).
Three separate cultures were utilized in these experiments, with at least 10 fields
in total for each treatment group, representing over 1,000 neurons for each
group. Scale bars, 100µm.

Modulation of tyrosine phosphorylated proteins in response to ADAMTS4
Since ADAMTS4 appears to exert its effects on neurite outgrowth
independent of its proteolytic activity, it is possible that ADAMTS may be
signaling the cell by binding and acting at the cell surface. Significant evidence is
available showing that ADAMTS protein is localized to the ECM and cell surface
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(Kuno and Matsushima, 1998; Kuno et al., 1999; Gao et al., 2004a). Since
neurite outgrowth has been shown to be mediated in part by tyrosine kinase
signaling, neurons treated with ADAMTS4 were examined for elevated
abundance of intracellular proteins containing phosphorylated tyrosine residues
using an anti-phosphotyrosine antibody in neuronal lysates. Neurons were
treated with 50nM ADAMTS4 and extracted after 20, 40 and 60 minutes of
incubation, lysates subjected to Western blot and probed with antiphosphotyrosine antibody. Increases in the abundance of several
phosphotyrosine-containing proteins of differing molecular weights were
observed after stimulation with ADAMTS4 (Fig. 13F). Robust up-regulation of a
50kD (Fig. 13C), 115kD (Fig. 13D) and >120kD (Fig. 13E) signal was detected at
60 minutes after addition of ADAMTS4, although the peak of the time-course was
somewhat inconsistent among experiments. Modest increases were seen in a
species at ~40kD (Fig. 13A, B).
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Figure 13. Tyrosine residue phosphorylation in total protein extract from neurons
after treatment with human recombinant ADAMTS4. Representative immunoblot
showing protein bands immunoreactive with anti-phosphotyrosine antibody in
extracts from neurons, at 5 days in culture and treated with culture medium or 50
nM ADAMTS4 for 20, 40 and 60 min. Proteins immunoreactive for phosphotyrosine were observed at several molecular weights, 42 (A), 44 (B), 50 (C), 115
(D), >120 (E). Protein bands from this single experiment were quantified by
densitometry and values are shown in panel (F) indicate increases in band
density for proteins at several different molecular weights, especially prominent is
a band at about 40 kD. This blot is from a representative experiment and results
were similar in three replicate experiments.
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Modulation of MAP kinase (ERK1/2) in response to ADAMTS4
The increase in the abundance of phosphotyrosine-containing proteins
around 40 kD led us to examine the possibility that the effects on neurite
outgrowth were mediated by ERK1/2, an intracellular factor known to have
effects on neurite outgrowth. Thus, neuronal extracts were examined by
Western blot and probed with anti-"pan" ERK1/2 antibody and anti-phosphoselective ERK1/2 antibody to determine if any changes were occurring in the
ratio of activated (phospho) to total ERK1/2 protein in response to ADAMTS4.
Marked increases in activated 42/44kD ERK1/2 were detected after ADAMTS4
treatment (Fig. 14A-D), but there was some variability in the time of maximum
stimulation. However, elevations in the phospho-ERK1/2 / total ERK1/2 ratio
were observed in four separate independent experiments.
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Figure 14. ERK1/2 is activated in neurons in response to treatment with human
recombinant ADAMTS4.
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Figure 14. ERK1/2 is activated in neurons in response to treatment with human
recombinant ADAMTS4. Representative blots (A and B) and densitometric
values of immunoreactive bands (C and D) of ERK1/2 immunoreactivity in
extracts from neurons at 5 days in culture and treated with ADAMTS4. Culture
medium vehicle or human recombinant ADAMTS4 at 50 nM was added to
neuronal culture medium and cell lysates were collected 20, 40 and 60 minutes
after treatment, the lysates subjected to SDS-PAGE and Western blotting using
anti-42/44kD phospho-ERK1/2 (A) and anti-pan-ERK1/2 (B) antibodies.
Densitometry of the immunoreactivity bands was quantified and the ratio of
phospho-ERK1/2 to pan-ERK1/2 was calculated for each sample and for each
isoform of ERK 1/2. (C) ratio of 42 kD activated phospho-ERK to pan- 42 kD
ERK, (D), ratio of 44 kD activated phospho-ERK to pan- 44 kD ERK. Marked
and apparently sustained increases in activated ERK1/2 were observed in
response to treatment with ADAMTS4 This experiment was repeated four times,
with increases seen in each experiment, however, the time of the peak
magnitude of the increase was variable among experiments, Thus, results from
a single, representative experiment is shown.

Neurite outgrowth in the presence of MEK inhibitors
To determine whether the MAP kinase pathway(s) was mediating the
neurite growth promoting effects of ADAMTS4, neurite outgrowth was quantified
in cultures treated with selective MAP kinase inhibitors or their inactive analogs
(Fig.15). The MAP kinase inhibitor PD98059 (Fig. 15A) was added at 10 and
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25µM, and neurons were treated with U0126, a potent inhibitor of MEK-1 and -2,
at 10, 25 and 50µM (Fig. 15B). Neurons were treated with the inactive analog of
U0126, U0124 as a control. The inhibitors were used alone or thirty minutes
before the addition of 50nM ADAMTS4, and the neurons were fixed,
immunostained and photographed. Neurite outgrowth was quantified by the
same procedure as the protein treatment experiments. All neurites were traced
in a particular field, area occupied by the tracing was determined and expressed
as area occupied by neurite tracings divided by the number of neurons in the
field to yield µm2 neurite tracing/neuron. ADAMTS4 at 50 nM was effective in
enhancing neurite outgrowth (Fig. 15A-C). PD98059 treatment alone did not
significantly alter neurite outgrowth in the absence of ADAMTS4, and was
comparable to control levels at 10 and 25µM (Fig. 15A). However, when added
to cultures stimulated with ADAMTS4, PD98059 completely inhibited the neurite
outgrowth promoting effects of ADAMTS4 (Fig. 15A). When the MEK-1,-2
inhibitor, U0126 was incubated with neurons in the presence of ADAMTS4, it
also inhibited neurite outgrowth induced by the protease (Fig. 15B), yet at the
highest dose tested, the drug appeared to be neurotoxic (not shown). The
inactive analog of U0126, U0124, did not influence ADAMTS4 induced neurite
outgrowth at 25 and 50 µM (Fig. 15C). At the concentrations for these
experiments, the diluent used for each drug, DMSO, alone did not affect neurite
outgrowth (data not shown). These results suggest an involvement of the MAP
kinase signaling pathway in ADAMTS4-stimulated neurite outgrowth.
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Figure 15. MAP kinase inhibitors attenuate neurite outgrowth induced by human
recombinant ADAMTS4 treatment
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Figure 15. MAP kinase inhibitors attenuate neurite outgrowth induced by human
recombinant ADAMTS4 treatment. PD98059, an inhibitor of MAP kinase (A)
U0126, a potent inhibitor of MEK-1 and -2 (B) and U0124, an inactive analog of
U0126 (C) were added to the culture medium of neurons at 2 and 5 days in
culture to determine whether inhibition of the MAP kinase could influence the
growth of neurites induced by ADAMTS4. Cells were treated with vehicle
(DMSO) or inhibitor alone or with inhibitor thirty minutes before the addition of
50nM ADAMTS4, followed by fixation, immunostaining and quantification of
neurite outgrowth by tracing neurites on day 6 of the culture. Area occupied by
neurites (µm2) from neurite tracings was divided by number of neurons in the
field to generate a mean ± SEM (µm2/neuron). Each MAP kinase inhibitor
significantly and dose-dependently impaired the neurite outgrowth promoting
effects of ADAMTS4 with little effect on basal neurite outgrowth with the
exception of high doses of U0126 which appeared to be toxic toward the
neurons. * signifies p ≤ 0.05 compared to "control" treatment; ** signifies p ≤
0.05 compared to treatment with 50 nM ADAMTS4 alone. This experiment was
performed using an independent culture and at least 10 fields were examined for
each treatment group representing about 75 neurons per treatment group.
Similar data was obtained when the experiment was repeated.

Discussion
Several rather recent studies have provided the most direct evidence to
date for the involvement of matrix-degrading metalloproteinases in neural
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plasticity in the CNS. Most of these experiments were conducted in vivo and
demonstrated increased expression of matrix-cleaving proteinases during
conditions of regeneration and/or neuronal sprouting (Szklarczyk et al., 2002;
Yuan et al., 2002; Mayer et al., 2005) or synaptogenesis (Kim et al., 2005) and
that blockade of metalloproteinase activity during a critical period may impede
neural plasticity mechanisms (Reeves et al., 2003). In at least two of these
studies, a PG crucial to the plastic response was identified and shown to be an in
vivo substrate for an active metalloproteinase (Yuan et al., 2002; Mayer et al.,
2005). Data from in vitro studies has been limited to peripheral neurons and has
shown that metalloproteinases enhance penetration of neurites into the basal
lamina (Nordstrom et al., 1995) and potentiate nerve growth factor-induced
neurite extension in PC12 cells (Shubayev and Myers, 2004). In addition in
peripheral nerve, metalloproteinase cleavage of a PG converted the growth
environment from an inhibitory to a permissive one, allowing for elongation of
dorsal root ganglion neurons (Zuo et al., 1998). In the present study, ADAMTSs
were examined for their ability to induce neurite outgrowth in vitro in the absence
of any other classical growth factors. The ADAMTSs used in this study are
proteases particularly adept at cleaving aggregating, CS-containing PGs that are
abundantly expressed in the CNS.
Transfection of ADAMTS4 cDNA into primary rat neurons resulted in
enhanced neurite growth compared to neurons transfected with vector alone,
when neurons were grown on an astrocyte monolayer. The initial interpretation
was that elevated ADAMTS4 expression resulted in increased cleavage and/or
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degradation of CS-containing PGs present in the astrocyte monolayer (Hamel et
al., 2005). Thus, the matrix was more permissive toward neurite outgrowth after
being released from the inhibitory effects of the PGs (Zuo et al., 1998). However,
when neurons were cultured directly on a poly-L-lysine/laminin substrate without
an astrocyte monolayer, the results were the same, ie. ADAMTS4 transfected
neurons showed greater neurite outgrowth compared to vector transfected
neurons. This was puzzling since the abundance of matrix proteins produced in
neuronal cultures is markedly lower than that found on astrocyte monolayers. To
more fully characterize whether proteolytic activity was an essential component
in the action of the ADAMTSs in promoting neurite growth, neurons were
transfected with a construct encoding an inactive point mutant of ADAMTS4.
This construct contains a point mutation in the catalytic domain of ADAMTS4
resulting in an inactive protease, yet all other domains are identical to the wildtype protein (Gao et al., 2002). Neurons transfected with the mutant construct
were at least as effective as the construct encoding the wild-type, active
protease, indicating that proteolytic activity was not required for ADAMTS4 to
stimulate neurite extension. It also suggests that ADAMTS4 may be acting by
engagement with a cell surface protein, as mounting evidence indicates that
certain biological actions are stimulated by metalloproteinase binding to cell
surface signaling molecules, especially integrins (Conant, 2005), independent of
proteolytic function. Regarding the ADAMTSs, these proteinases avidly bind to
heparan and may be anchored to the cell surface or the ECM via its
thrombospondin motif and/or spacer region (Kuno and Matsushima, 1998; Kuno
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et al., 1999). ADAMTSs bind to heparan sulfate or CS chains found typically
attached to core protein PGs, and this protein-glycosaminoglycan interaction is
important for substrate recognition (Tortorella et al., 2000; Flannery et al., 2002;
Kashiwagi et al., 2004). Most recently, indirect evidence suggests that
ADAMTS4 may bind to the cell surface heparan sulfate PG, syndecan-1, in
chondrocyte-like cells in culture (Gao et al., 2004a) and orient the protease for Cterminal truncation by another cell surface metalloproteinase. Whether binding of
syndecan-1 by ADAMTS4 directly activates intracellular signaling mechanisms is
not known.
Compelling evidence presented here indicates that one intracellular
signaling mechanism induced by ADAMTS4, presumably by interacting with a
cell surface protein, is the MAP kinase cascade. ADAMTS-induced neurite
extension is completely dependent on activation of this pathway since
pharmacological inhibition of ERK1/2 kinase activity reversed the effect. Data
from previous investigations convincingly point to a crucial role for MAP kinase in
process outgrowth from a variety of neuronal-like cell types. Neurite outgrowth
on the adhesion protein L1 in B35 neuroblastoma cells requires MAP kinase
activation (Schmid et al., 2000) and expression of Eph8 stimulates MAP kinase
and neurite outgrowth in NG108-15 cells (Gu et al., 2005). Neuregulin-1
activation of erbB receptors activates MAP kinase and stimulates hippocampal
neuronal differentiation and neurite extension and arborization (Gerecke et al.,
2004). These data clearly support the concept that MAP kinase activation is
involved in, or is at least associated with, neurite extension.
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Additional data indicates that heparan sulfate-containing proteins
transduce signals resulting in the activation of MAP kinase. Basic fibroblast
growth factor (FGF)-2 binds heparan sulfate on the PG, agrin, to activate the
ERK1/2 signal and modulate neurite outgrowth in PC-12 cells and retinal neurons
(Kim et al., 2003). It may be that ADAMTS mobilizes and activates bFGF by
interacting with a heparan sulfate-containing PG, such as agrin, at the surface of
cortical neurons, although agrin expression is much lower on CNS neurons
compared to those from the periphery. As mentioned above, another possible
ADAMTS binding partner is syndecan. Connective tissue growth factor, (CCN2), a protein that like ADAMTS4, contains a thrombospondin type-1 motif, is
known to bind syndecan-2 and activate ERK1/2 (Gao et al., 2004b). It is
plausible that the ADAMTSs bind syndecan and activate the MAP kinase
cascade, thereby increasing neurite extension. We have demonstrated that
ADAMTSs induce MAP kinase signaling in primary rat cortical neurons, an action
essential for ADAMTS-induced neurite outgrowth. Compared to neuron-like cell
lines which are the cells typically used to demonstrate signaling by the MMPs,
the primary cultured neurons from embryonic rat cortex used in these studies are
a model that more closely parallel neurons in vivo in their receptor and signaling
ensemble.
One primary candidate, functional motif in the structure of ADAMTS4 that
may be responsible for enhancing neurite elongation is the type-1
thrombospondin motif. Thrombospondin itself enhances neurite outgrowth
(O'Shea et al., 1991) and the thrombospondin type-1 repeats of SCO-spondin
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bind to α1β1 integrin to stimulate cell process extension in B104 cells, a neuronlike cell line (Bamdad et al., 2004). Furthermore, other ECM proteins that contain
thrombospondin-like motifs, such as heparin-binding growth-associated molecule
(HB-GAM, also known as pleiotrophin) and midkine, increase neurite outgrowth
in hippocampal neurons (Raulo et al., 2005). Thus, there is strong evidence that
thrombospondin-like regions of various proteins expressed in and secreted by
neurons (or astrocytes via a paracrine action) may affect neural plasticity.
In sum, these results indicate that the ADAMTSs, similar to the MMPs
(Conant, 2005), exert biological activities independent of their proteolytic activity,
one of them that induces extension of neurites in primary cultured embryonic
neurons. The particular motif on the ADAMTSs responsible for stimulating this
effect is not known, but evidence from others points to the thrombospondin type
1 repeat or the spacer region. Since this carboxy-terminal may bind to heparan
sulfate chains, the cell surface molecules that bind the ADAMTSs likely differ
markedly from the MMPs, molecules that do not contain a thrombospondin
repeat. Preliminary, unpublished data from our laboratory indicates that the
ADAMTSs stimulate neurite outgrowth on a CS-containing substrate that is laid
on plastic in vitro. It will be interesting to determine whether this activation of
neurite extension is dependent on or independent of ADAMTS proteolytic activity.
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Chapter 3: ADAMTS4 (A Disintegrin and Metalloproteinase with Thrombospondin
Motifs 4) Inhibits Maturation of Dendritic Spines in Neurons in vitro

Abstract
Dendritic spines are tiny protuberances that extend from the dendritic
shaft which are the sites for the majority of excitatory neurotransmission in the
central nervous system (CNS). Alterations in dendritic spine morphology are
now recognized as a reliable indicator of changes in synaptic function. The
components of the extracellular matrix (ECM) may mediate plasticity in the CNS
and the most abundant family of proteins which make up the ECM, the lectican
family of chondroitin sulfate (CS)-containing proteoglycans (PG), play important
roles in cell adhesion, migration and inhibition of neurite outgrowth. Little is
known about whether lecticans modulate synaptic plasticity, although indirect
evidence indicates that they may do so. Proteases that cleave and degrade
various components of the ECM are increasingly recognized as significant
contributors to the functional state of the ECM, and proteolysis of lecticans may
affect plasticity. Increased proteolysis of lecticans by members of the ADAMTS
family of proteases, enzymes well known to cleave lecticans, may change
synaptic morphology and plasticity in neurons in vitro. To test this hypothesis,
neurons were cultured and increased levels of ADAMTS4 were introduced by
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direct treatment with recombinant protein or by transfection of neurons with a
DNA expression vector to drive the expression of ADAMTS4. Various
measurements of dendritic spine morphology were made several time points
after addition. Furthermore, levels of synaptic markers which correlate with
synaptic abundance were quantified by ELISA and immunostaining. After
ADAMTS4 treatment, several alterations were detected in dendritic spine
morphology, including increased overall length of spines and an increased
percent of protrusions that were defined as filopodia. A concurrent decrease in
PSD-95 staining was detected on the neurites of young neurons overexpressing
ADAMTS4 or expressing proteolytically-inactive mutant ADAMTS4 protein.
Thus, ADAMTS4 may promote plasticity in neurons in vitro by inhibiting the
formation, maturation and/or stabilization of synapses.

Introduction
The significance of alterations in synaptic structure has been
acknowledged for its correlation with functional changes in the brain. One such
structural modality in the brain is the dendritic spine, which is a small protrusion
that extends from the dendritic shaft and most often contains a single synapse
representing the site for the majority of excitatory neurotransmission in the CNS
(Yuste and Bonhoeffer, 2001). Dendritic spines were identified in the 19th
century by Ramon y Cajal and sometimes are formed as long, thin protrusions
known as filopodia which may mature into shorter spines of varying shapes (Ziv
and Smith, 1996; Fiala et al., 1998; Harris, 1999), although a spine can
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circumvent filopodial morphology and appear as a spine outright (Engert and
Bonhoeffer, 1999; Marrs et al., 2001). In cultured neurons, spines are more
numerous in mature neurons while filopodia are more abundant in young
neurons (Dailey and Smith, 1996). Filopodia are highly motile and spines
themselves are dynamic structures (Dunaevsky et al., 1999; Parnass et al., 2000;
Bonhoeffer and Yuste, 2002), and this motility has been observed with twophoton laser scanning microscopy (Grutzendler et al., 2002; Majewska et al.,
2006; Yasuda et al., 2006). Interestingly, changes in spine morphology and
density result from the induction of long term potentiation (LTP) and enhanced
neuronal activity. Furthermore, abnormal morphology of dendritic spines is
associated with a host of cognitive disorders that includes autism, mental
retardation and even disorders that involve neurodegeneration such as animal
models of Alzheimer’s disease (Hering and Sheng, 2001; Yuste and Bonhoeffer,
2001; Nimchinsky et al., 2002).
PGs of the ECM are emerging as important extracellular modulators of
neural plasticity, and although most evidence that points to this role is indirect
and descriptive, it encourages further research into the ability of PGs to regulate
synaptic maturation and function. PGs of the lectican family, brevican, neurocan,
versican and aggrecan contain CS side chains, and their developmental
expression is coincident with the maturation and stabilization of synapses within
the CNS (Yamaguchi, 2000). Furthermore, brevican levels remain high in the
adult and throughout the life of the animal, suggesting these PGs may play a role
in the development of synaptic stabilization (Milev et al., 1998). In addition to
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temporal evidence, localization studies demonstrate a role for brevican in
synaptic stabilization. Brevican is deposited around but not over the synapse,
effectively “walling-off” the synapse in an envelope of ECM, and it is thought that
the presence of this lectican reinforces the strength of the synapse (Yamaguchi,
2000). Knock-out studies have not shown a clear necessity for lecticans in
synaptic stabilization, however, further studies are needed in these experiments
to guard against making generalizations without knowing whether compensatory
increases in the expression of other lecticans may account for the lack of
phenotype (Zhou et al., 2001; Brakebusch et al., 2002; Rauch et al., 2005). At
any rate, brevican knockout mice display impaired LTP, which interestingly is an
effect that may be replicated by infusion of anti-brevican antibody in the brain
(Brakebusch et al., 2002).
ADAMTSs, a family of glutamyl endopeptidases, cleave PGs, and it has
been proposed that proteolytic alterations in matrix components can lead to
plastic changes, however it is unknown whether any effects seen by the
ADAMTSs are due to proteolysis of PGs or by a signaling component in their
own right as we have shown for neurite outgrowth. Several studies indicate a
role for ADAMTSs in response to injury or inflammation. Treatment of rat
neurons in culture with amyloid ß results in increased levels of ADAMTS4
transcript (Satoh et al., 2000). Kainate-induced excitotoxic lesion induced an
upsurge of mRNA for ADAMTS1 and 4 with a concurrent increase in the
proteolytic fragment of brevican produced by ADAMTS cleavage (Yuan et al.,
2002). Additionally, ADAMTS1 was increased in the spinal cord of rats that
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underwent axotomy (Sasaki et al., 2001). ADAMTS1, but not ADAMTS5 is
increased in Down Syndrome, Pick’s Disease and Alzheimer’s Disease (Miguel
et al., 2005). Again, it was not certain whether these changes were due to
proteolysis or signaling events induced by ADAMTSs, since our lab has
previously shown that ADAMTS4 activates the mitogen-activated protein kinase
(MAPK) pathway to increase neurite length (Hamel et al., 2005). Proteases
belonging to a related family, the matrix metalloproteinases (MMP), have been
shown to induce signaling in cells in the absence of proteolytic action.
This study seeks to elucidate whether ADAMTSs modulate synaptic
contacts, as measured by changes in dendritic spine morphology and
quantification of immunoreactivity for key synaptic markers related to synaptic
abundance using ELISA and immunostaining. Two presynaptic markers,
synaptophysin and synaptosomal-associated protein of 25kD (SNAP-25) and one
post-synaptic marker (localized to the scaffolding of dendritic spines), postsynaptic density-95 (PSD-95), will be quantified. Here we show that in cultured
neurons, spine lengths were increased as were the proportion of immature
filopodia in response to treatment with ADAMTS4 recombinant protein.
Furthermore, decreases in the levels of PSD-95, a postsynaptic marker highly
enriched in the post-synaptic scaffolding, were detected were detected in
response to increased expression of ADAMTS4 or expression of proteolyticallyinactive mutant ADAMTS4. Our findings appear to identify a role for ADAMTS4
in modifying synaptic maturation.
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Materials and Methods
Primary neuronal culture
Primary cultures of neurons were prepared from cerebral cortex of
embryonic day 18 Sprague Dawley (Harlan, Indianapolis) rat pups in Dulbecco's
Modified Eagles Medium containing 10% horse serum as described previously
(Hamel et al., 2005). After isolation, neurons were plated directly on substratecoated glass coverslips or subjected to transfection by electroporation before
plating on the same coverslips. After twenty-four hours, culture medium was
exchanged for serum-free neuronal growth medium (Neurobasal medium
(Invitrogen) containing B-27 defined supplement (Invitrogen), 0.5mM Glutamax II
(Gibco, Carlsbad), 25µM glutamate and 1% antibiotic/antimycotic solution
(Gibco)) for the duration of the culture.

Transfection by electroporation
DNA expression constructs of ADAMTS4 were made for transfection of
primary rat cells from forebrain of embryonic day 18 rat pups. A cDNA for
ADAMTS4 (Gao et al., 2002), and an inactive point mutant of ADAMTS4 362
(E→Q) (Gao et al., 2004a) that were inserted into pcDNA (Invitrogen), were
restricted with Xba I and Kpn I (Promega, Madison), the ADAMTS4 (or mutant)
fragment purified from an agarose gel and ligated into linearized pCMS plasmid,
a dual promoter vector that expresses enhanced green fluorescent protein
(EGFP) driven by SV40 (Clontech, Mountain View, CA), and the inserted gene
driven by the cytomegalovirus promoter. After cells from cerebral cortex of E18
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SD pups were isolated, 5x106 cells were centrifuged and resuspended in 100µl
rat nucleofector solution (Amaxa Biosystems, Gaithersburg, MD). The cells were
transferred to a cuvette and pCMS, pCMS-ADAMTS4 or pCMS-ADAMTS4
mutant were added and the cuvette subjected to electric current using the
Nucleofector electroporator (Amaxa Biosystems) with either the O-03 or G-13
time and current pre-programmed by the manufacturer. Immediately after
transfection, 500µl of pre-warmed, 37°C Dulbecco's Modified Eagles Medium
with 10% fetal calf serum was added to the cell suspension, and the cells were
transferred to a sterile microcentrifuge tube until plating. The transfected
neurons were plated on glass coverslips pre-coated with the laminin/poly-L-lysine
substrate. Neurons were allowed to grow for 8-11 DIV or 20-22 DIV. After this
time, cells were washed one time in PBS, fixed in 4% room temperature
paraformaldehyde for twenty minutes, and washed an additional three times with
PBS, followed by immunocytochemistry to stain the synaptic proteins,
synaptophysin, SNAP-25 and PSD-95.

Immunocytochemistry
Neuronal cultures fixed as described above were incubated for one hour in
blocking buffer containing 10% normal goat serum (NGS), 0.3% triton-X-100 and
1M lysine in PBS at room temperature. Cells were incubated for 2 hours at room
temperature in dilution buffer (PBS, 10% NGS, 0.3%Triton-X-100) containing
rabbit anti-synaptophysin (Dako, Carpinteria, CA) diluted to 1:200, rabbit antiSNAP-25 (Sigma, St. Louis, MO) diluted to 1:200 or mouse anti-PSD-95
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(Chemicon, Temecula, CA). The cells were washed three times in PBS and
Alexa Fluor 588 goat anti-mouse (or goat anti-rabbit) IgG fluorescent secondary
antibody (Invitrogen, Carlsbad, CA) was incubated at a concentration of 1:500 for
1 h and the coverslips washed three times in PBS. The coverslips were then
mounted on slides with Vectashield (Vector Laboratories, Burlingame, CA)
fluorescent mounting medium and the cells were visualized with epifluorescence.

Quantification of synaptic marker immunostaining
Levels of immunoreactivity of synaptic proteins expressed by transfected
cells were quantified. Transfected and immunostained cells were visualized
under epifluorescence using a Zeiss Axioskop microscope interfaced with an
Axiocam (Zeiss, Thornwood, NY) digital camera and captured with uniform
exposure time with Openlab software (version 3.1.4, Improvision, Lexington,
MA). Transfected cells were visualized using the FITC filter, and once a transfect
was located, the rhodamine filter was then employed to capture an image of the
red synaptic marker staining on the transfected cell. Images were analyzed
using NIH ImageJ version 1.35S (NIH, Bethesda, MD). To quantify optical
density of the immunostain on the soma, the maximum optical density of
immunostain contained within a 50µm2 square on the neuronal cell body was
quantified by NIH ImageJ. For quantification along a neurite, a 20µm segment
was analyzed. This analysis was performed with young (8-11 DIV) and mature
(20-22 DIV) neurons. Quantification was performed with the treatment unknown
to the experimenter using 570 neurons from 2 cultures, and data were
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statistically assessed by ANOVA followed by Newman-Keuls multiple comparison
post-test. p<0.05 was considered a significant difference between groups.

ADAMTS4 protein treatment
For dendritic spine experiments, 2.5x105 neurons were cultured on 22 mm
glass coverslips, and for protein extraction experiments, 3.625x106 neurons were
cultured on 100mm tissue culture dishes for 8-11 DIV (young) or 20-22 DIV
(mature). Purified recombinant ADAMTS4, provided by Roche Biosciences, was
diluted in Neurobasal medium plus 0.1% bovine serum albumin (BSA) and
syringe filtered to sterilize. BSA was added to prevent adherence of the
recombinant protein to the filter. Each of the ADAMTS protein preparations
contained low, but detectable levels of endotoxin using the LAL assay (Cambrex,
Walkersville, MD) that were comparable to the BSA controls. Filtered 50nM
ADAMTS4 was applied to the culture and the cells were incubated for 2-3 days.
Control wells received a matched volume of filtered Neurobasal medium plus 1%
BSA. After the incubation was complete, the neurons were processed for ELISA
or dendritic spine examination.

Dendritic spine analysis
Neurons treated with 50nM ADAMTS4 human recombinant protein were
used for the examination of dendritic spines. After protein treatment, neurons
were fixed in 4% paraformaldehyde as described above followed by incubation
with a fluorescent-tagged, actin binding protein, Alexa-Fluor 488 phalloidin
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(Molecular Probes/Invitrogen), at a dilution of 1:500 in 2% NGS and 0.3%TritonX-100 in PBS for 20 minutes at room temperature, followed by an additional
three rinses in PBS. Neurons were imaged using a Leica TCS SP2 confocal
scanning laser microscope with a 63X objective (numerical aperture, 1.4) with a
zoom of 2 and z-sectioned in increments of 0.3µm. 2D maximum reconstructions
were generated from the z-stacks and utilized for quantification of spines. NIH
ImageJ was used to perform several measurements of the dendritic spine (Harris
et al 1992, Koh et al, 2002). The length of the spine was measured from the
dendrite to the tip of the spine; maximum spine head diameter and the minimum
neck diameter were measured as well. The ratio of the measurements of
maximum head diameter to the minimum neck diameter were used to place
spines into categories of filopodial, stubby, mushroom and thin (Zagrebelsky M et
al, 2005;Peters & Kaisrman-Abramof, 1969; Nakayama AY et al, 2000). Any
protrusion >3µm in length was considered a filopodia. A spine with a length
≤3µm with a ratio of head to neck≥1.5 was considered a mushroom spine. Thin
spines had a head/neck ratio <1.5 with 1≥ Length ≤3. Stubby spines had a
head/neck ratio <1.5 with Length ≤1. All measurements were performed blindly
with the experimental group being quantified unknown to the personnel.
Statistical significance was assessed by unpaired t-test, and a p<0.02 was
considered significant.
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ELISA
After control or 50nM ADAMTS4 treatment, RIPA buffer (50mM Tris,
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% triton-X-100, 1% sodium
deoxycholate, 0.1% SDS) with protease inhibitor cocktail (set III, Calbiochem,
San Diego) was added to the culture on ice to extract protein, followed by
analysis by ELISA to determine the levels of synaptic markers. ELISAs were
conducted to measure immunoreactivity of synaptophysin, SNAP-25 and PSD-95
were performed. Briefly, coating antibody in buffer (0.01M phosphate buffer) was
applied to the EIA/RIA high-binding 96-well plates (Costar) with: mouse antisynaptophysin (Chemicon) at a dilution of 1:250, mouse anti-SNAP-25
(Chemicon) at a dilution of 1:200 or mouse anti-PSD-95 (Chemicon) at a dilution
of 1:100. The plates were agitated overnight and the antibody was allowed to
adhere to dryness at room temperature. The wells were then washed with
sample/wash buffer (PBS with .05% Tween-20) one time. Blocking buffer (PBS
with 0.05% Tween-20 and 5% dry milk) was applied to the wells and incubated at
room temperature for 1 hour with agitation, followed by washing and applying cell
extract diluted in sample/wash buffer for two hours at room temperature with
agitation. Sample was then washed from the well followed by the addition of
primary antibody for two hours in buffer: rabbit anti-synaptophysin (Dako) at a
dilution of 1:2000, rabbit anti-SNAP-25 (Sigma) at a dilution of 1:1000 and sheep
anti-PSD-95 (Zymed) at a dilution of 1:100. The wells were washed three times
and secondary antibody applied in buffer for one hour: (goat anti-rabbit IgG-HRP
(Chemicon) at 1:5000 or anti-sheep/goat (Chemicon) at a dilution of 1:1000).
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Blue reaction product was detected after the application of TMB (Sigma) and
reaction stopped with 1M H2SO4. Absorbance levels were detected with a
Wallac Victor2 1420 multilabel counter (Perkin Elmer, Wellesley, MA) interfaced
with Workout software (version 1.5, Perkin Elmer), and these levels were
normalized per µg protein applied to the well. The time course of synaptophysin
and PSD-95 levels in untreated, control neurons was performed with cell extracts
from three neuronal cultures and means from experimental groups compared
using ANOVA and pair-wise comparisons were made with Newman-Keuls posthoc test (GraphPad, San Diego, CA). A p<0.05 was considered a significant
difference between groups.

Results
Analysis of spine density and length
Changes in the morphology of dendritic spines are routinely used as
measures of synaptic maturation, and to determine whether ADAMTS4 could
affect dendritic spine morphology, neurons were subjected to ADAMTS4 or
vehicle treatment, fixed in 4% paraformaldehyde and spines detected with the
fluorescent-tagged actin-binding protein, phalloidin (Fig. 16 A, B). Spine length,
maximum head diameter and minimum neck diameter were quantified using NIH
ImageJ, and these measurements were used in several analyses. The mean
density of spines was calculated by averaging the number of spines measured
per 10µm segment of dendrite analyzed for control and ADAMTS4-treated young
and mature neurons (Fig. 16 C), and no alterations in spine density was detected
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with treatment with ADAMTS4 in either young or mature neurons. Since longer
protrusions often indicate less mature spines, mean spine length was calculated
by averaging the lengths for each protrusion measured (Fig. 16, D), and
ADAMTS4 treatment significantly increased the lengths of protrusions (spines
and filopodia included) in young and mature neurons.

Figure 16. Human recombinant ADAMTS4 increases dendritic protrusion length
in young and mature neurons.
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Figure 16. Human recombinant ADAMTS4 increases dendritic protrusion length
in young and mature neurons. Photomicrographs of primary rat cortical neurons
treated with culture medium containing BSA (A) or 50nM ADAMTS4 (B) are
depicted and quantifications of protrusion density (C) and protrusion length (D)
are shown, which were examined at 8-11 DIV (Young) or 20-22 DIV (Mature). At
the end of culture, dendritic spines were visualized by using the Alexafluor 488conjugated actin binding protein, phalloidin. Spines were analyzed with NIH
ImageJ, and mean protrusion density was calculated by averaging the number of
protrusions (spines and filopodia) per 10µm segment of dendrite measured (C),
and mean spine length was calculated by averaging lengths for all protrusions
measured (D). Treatment with ADAMTS4 did not significantly alter spine density
(C), however, spine length was significantly increased (D) in young and mature
neurons with ADAMTS4 treatment. (* p ≤ 0.02 compared to young control, ** p ≤
0.02 compared to mature control). Three separate cultures were utilized in these
experiments. n=133, young control; 167 young ADAMTS4; 211, mature control;
115, mature ADAMTS4, C. n=763, young control; 977 young ADAMTS4; 1289,
mature control; 750, mature ADAMTS4, D.

Analysis of dendritic spine morphology
Since changes in spine morphology can reflect changes in synaptic
function, spines were categorized into morphological classes utilizing the
measurements detailed above to determine whether ADAMTS4 could alter the
proportion of spine types. The morphology of spines is used as an indicator of
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their maturity, with filopodia defined as precursors to spines, thin spines being
the most immature spines followed by mushroom spines being more mature and
stubby spines the most mature. The percentages of different spine types was
calculated by averaging the numbers of different types divided by the total
number of spines measured for each 10µm segment of dendrite measured. In
accordance with the previous finding of ADAMTS4 increasing length, ADAMTS4
treatment increased the percentage of filopodia, the longest in length of the
morphological categories in both young and mature neurons (Fig. 17, top left
panel). ADAMTS4 treatment also significantly increased the percentage of thin
spines while decreasing the percentage of stubby spines in mature neurons (Fig.
17, top right and bottom right panels).
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Figure 17. Treatment of primary neurons with ADAMTS4 alters the proportion of
various spine types.
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Figure 17. Treatment of primary neurons with ADAMTS4 alters the proportion of
various spine types. Percentages of filopodia, thin spines, mushroom spines and
stubby spines are depicted in neurons treated with culture medium containing
BSA (control) or 50nM ADAMTS4 examined at 8-11 DIV (Young) or 20-22 DIV
(Mature). At the end of the treatment period, dendritic spines were visualized by
using the Alexafluor 488-conjugated actin binding protein, phalloidin. Spines
were analyzed with NIH ImageJ, and mean percentage of type was calculated by
averaging the percentage of protrusion calculated for each 10µm segment
measured. Treatment with ADAMTS4 significantly increased the percentages of
filopodia in young and mature neurons (upper left panel), and significantly
increased the percentage of thin spines while reducing the percentage of stubby
spines in mature neurons (upper and lower right panels). (* p ≤ 0.02 compared
to young control, ** p ≤ 0.02 compared to mature control). Three separate
cultures were utilized in these experiments. n=133, young control; 167 young
ADAMTS4; 211, mature control; 115, mature ADAMTS4.

Quantification of localized synaptic proteins
Since changes were detected in the morphology of spines, we were next
interested in determining whether there would be concurrent alterations in
proteins enriched at the synapse, but before directly examining ADAMTS4
treated neurons, a time course detecting synaptic proteins was conducted in
control-treated neurons to verify that these ELISAs could detect maturational
changes in the expression of these synaptic proteins. Neurons were grown and
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cell proteins extracted at 5, 12 and 21 DIV. Synaptophysin levels increased in
control neurons as the culture aged (Fig. 18, upper panel). PSD-95 protein
levels showed a similar increase in individual cultures, however, due to variability
between these values, these increases were not statistically significant (Fig. 18,
lower panel).

Figure 18. Synaptic marker proteins increase with neuronal culture age.
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Figure 18. Synaptic marker proteins increase with neuronal culture age. Units of
synaptophysin (upper panel) and PSD-95 (lower panel) immunoreactivity per µg
protein measured by ELISA in neurons at 5, 12 and 21 DIV. Neurons were
grown under basal conditions, proteins extracted at days 5, 12 and 21 and
subjected to synaptophysin or PSD-95 ELISA. Units of immunoreactivity were
normalized per µg protein, and significant increases in immunoreactivity are
detected in synaptophysin (upper panel), but not PSD-95 (lower panel) as DIV
increases. *, significant difference from 5DIV, p<0.05, **, significant difference
from 12 DIV, p<0.05. This experiment was performed three times using cells
isolated from separate litters of rat pups.

To determine whether ADAMTS4 treatment could lead to alterations in
synaptic protein levels, neurons were treated with ADAMTS4 or vehicle culture
medium containing BSA, the treatment continued for 2 days and cell proteins
extracted at 8-11 DIV (Young) or 20-22 DIV (Mature). Despite seeing clear
changes in dendritic spine morphology, no significant alterations in levels of
synaptophysin (Fig. 19, upper panel), SNAP-25 (Fig. 19, middle panel) or PSD95 (Fig. 19, lower panel) were observed in response to ADAMTS4 treatment.
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Figure 19. ADAMTS4 does not significantly alter synaptic protein levels.
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Figure 19. ADAMTS4 does not significantly alter synaptic protein levels.
Quantitative analysis of immunoreactivity of synaptophysin (upper panel), SNAP25 (middle panel) and PSD-95 (lower panel) in neurons treated with medium
containing BSA (control) or 50nM ADAMTS4 in neuronal proteins extracted at 811 DIV (young) or 20-22 DIV (mature)as measured by ELISA. Treatment was
incubated for 2-3 days followed by extraction of proteins and subjection to
synaptophysin, SNAP-25 or PSD-95 ELISA. Units of immunoreactivity were
normalized per µg protein. These experiments were performed three times
utilizing cell cultures derived from 3 separate litters of rat pups.

Alterations in immunostaining of synaptic proteins
Since ADAMTS4 was clearly affecting dendritic spine morphology, yet no
changes were seen in synaptic proteins as detected by ELISA, changes in
synaptic markers were examined by immunocytochemistry to clarify the previous
findings, and potentially find localized changes in synaptic marker expression
that were not detected with the sensitivity of ELISA. Instead of protein treatment,
these neurons were transfected with a vector to drive the expression of
ADAMTS4, mutant ADAMTS4 or empty vector (Fig. 20, A, C, E). Neurons were
transfected and allowed to grow for 8-11 DIV or 20-22 DIV, and following this, the
neurons were fixed and immunostained for synaptophysin, SNAP-25 and PSD95 (Fig. 20, B, D, F). Transfected neurons were visualized by their green color
since the vector to drive the gene of interest contains a separate promoter to
drive the expression of EGFP, and once a transfected cell was visualized, red
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immunostaining of synaptic proteins on EGFP-expressing transfected neurons
was quantified for staining detected on the cell bodies and neurites of transfected
neurons. Experimental groups were compared to empty vector alone transfects,
and no changes were detected in immunostaining on cell bodies (Fig. 21, A-F),
however, there was a trend toward a decrease in PSD-95 levels in the cell bodies
of mature neurons (Fig. 21, F). When the immunostaining of synaptic proteins
was quantified on the neurites of transfected neurons, there was a significant
decrease in PSD-95 staining on the neurites of young neurons overexpressing
ADAMTS4 and expressing the ADAMTS4 mutant protein (Fig. 22, E).
Immunostaining of adjacent neurons was also quantified with no significant
correlations to ADAMTS transfection seen (data not shown).

Figure 20. Synaptic marker staining in transfected neurons. Neurons were
transfected with empty vector (E), a vector to drive the expression of ADAMTS4
(C) and a vector to drive the expression of proteolytically inactive mutant
ADAMTS4 protein (A), allowed to grow for various time points, fixed and
immunostained for synaptophysin (B), SNAP-25 (D) and PSD-95 (E). Neurons
pictured are 21 DIV. Scale = 5µm.
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Figure 20. Synaptic marker staining in transfected neurons.
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Figure 21. Alterations in levels of synaptic markers on neuronal cell bodies in
response to ADAMTS4.
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Figure 21. Alterations in levels of synaptic markers on neuronal cell bodies in
response to ADAMTS4. Primary neurons transfected with a vector to drive the
expression of ADAMTS4, an ADAMTS4 mutant construct, or controls transfected
with empty vector, and allowed to grow to a specific young (8-11 DIV, A, C, E) or
mature (20-22 DIV, B, D, F) time point after which the cells were fixed and
immunostained for Synaptophysin, SNAP-25 or PSD-95. For transfected cells,
the maximum optical density of immunoreactivity over a 50µm2 area of the cell
body was quantified for: Synaptophysin (A-B), SNAP-25 (C-D) or PSD-95 (E-F).
No significant alterations in immunostaining were observed in response to
ADAMTS4 or mutant ADAMTS4 transfection. 19≤n≥64 for each group
quantified.

Figure 22. Alterations in immunoreactivity of synaptic markers on neurites of
transfected neurons. Control, ADAMTS4 and mutant ADAMTS4-transfected
neurons were grown for 8-11 DIV (A, C, E) or 20-22 DIV (B, D, F), followed by
fixation and immunostaining for synaptic markers along a 20µm length of the
neurites of transfected cells. Optical density of synaptophysin (A-B), SNAP-25
(C-D) and PSD-95 (E-F) staining was quantified, and PSD-95 staining was
significantly reduced in ADAMTS4 and mutant ADAMTS4-transfected neurons.
*, significant difference from PCMS, p<0.05. 20≤n≥56 for each group quantified.
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Figure 22. Alterations in immunoreactivity of synaptic markers on neurites of
transfected neurons.
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Discussion
These studies present evidence to indicate that ADAMTS4 plays a role in
the maturation of dendritic spines. We show that ADAMTS4 treatment of primary
cultured neurons increases the proportion of immature, filopodial protrusions in
comparison to the proportion of filopodia in untreated cultures. Additionally, we
show that ADAMTS4 protein treatment of mature neurons converts mature
stubby spines to filopodia. This effect was correlated with a decrease in PSD-95
staining, especially in the neurites of young neurons. This effect appears to be
independent of the proteolytic action of ADAMTS4 in that these neurons were
cultured on poly-l-lysine/laminin substrate and in addition, transfection of a vector
to drive the expression of an inactive mutant ADAMTS4 resulted in a loss of
PSD-95 immunoreactivity. Thus, the presence of increased levels of ADAMTS4
could play a critical role in activating a plastic response in the adult CNS, or even
the loss of synapses associated with inflammation and neurodegenerative
disease.
The role of extracellular proteases in neural and synaptic plasticity is
largely unknown, although these proteases are increasingly recognized as
important mediators in the reorganization of the ECM that occurs during the
plastic response after injury. There is an absence of data examining whether the
ADAMTSs mediate synaptogenesis in the CNS, or whether they have a role at all
in vivo. The mechanism by which ADAMTS4 reverses or inhibits the maturation
of dendritic spines is currently unknown. Our studies indicate that this effect may
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be independent of the proteolysis since the proteolytically inactive mutant
ADAMTS4 reduced levels of PSD-95 in a similar fashion to native ADAMTS4.
Our laboratory has presented the first evidence to indicate that ADAMTSs
may act by signaling at the cell surface to mediate cell functions. Due to this
scant substantiation that ADAMTSs can act in a role other than proteases, we
turn to a related family of proteases, the matrix metalloproteinases (MMP), that
demonstrate that proteases can act in a signaling capacity. In fact, treatment of
neural cells with MMP-1, a collagen protease, decreases levels of cAMP and
activates a pertussis-toxin sensitive G protein-coupled receptor to stimulate the
release of MMP-9 (Conant et al., 2002). Furthermore, MMP-1 interacts with α2β1
integrin to stimulate dephosphorylation of Akt and induce neuronal death (Conant
et al., 2004). Additionally, MMP-7 was recently shown to transform mature
mushroom spines to immature filopodia, an effect very similar to those presented
here by ADAMTS4, and this action was independent of proteolysis by MMP-7
(Bilousova et al., 2006). Thus, it is highly likely that the ADAMTSs can act as
signaling molecules, and more than proteases.
The mechanism of ADAMTS4 action to inhibit the maturation of dendritic
spines is unknown. If this effect is independent of proteolysis, there are many
possibilities as to what the mediators may be. Our lab previously showed that
ADAMTS4 treatment induces activation of extracellular signal-related kinase
(ERK) 1/2 MAPK to increase neurite outgrowth, and other studies indicate that
phosphorylation of ERK1/2 leads to varied effects on synapses. Brain-derived
neurotrophic factor (BDNF) increases spine density in hippocampal CA1
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pyramidal neuronal cultures through activation of ERK1/2 (Alonso et al., 2004).
Furthermore, treatment of mature hippocampal neurons with semaphorin3A
activated ERK1/2 to reduce the staining intensity of PSD-95 and synaptophysin
(Bouzioukh et al., 2006). Thus, ERK1/2 activation could potentially lead to
modulations in synapses through its activation by ADAMTS4. There are several
other possibilities for mediators of synaptogenesis by ADAMTS4. The ADAMTSs
carry thrombospondin (TSP) type-1-like motifs and TSP itself is implicated in
synaptogenesis. TSP-1 and -2, which promote synaptogenesis in vitro as well as
in vivo, are expressed by immature astrocytes, but not by mature astrocytes, and
the authors suggest that this temporally regulated lack of expression by mature
astrocytes may explain why the adult CNS is largely unable to support
synaptogenesis (Christopherson et al., 2005).
Yet another possibility of the mechanism of action of ADAMTS4 is through
the actions of syndecan-2, a heparan sulfate-containing PG. Interestingly,
syndecan-2 induces mature dendritic spines in young neurons (Ethell and
Yamaguchi, 1999; Ethell et al., 2001), and what’s more, ADAMTS4 clearly binds
syndecan-1 (Gao et al., 2004). It is unclear whether this binding could affect
dendritic spine maturation. It may be that syndecan-1 sequesters ADAMTS4 to
block its effects in potentiating the immature morphology of filopodia. Further
studies are clearly needed to elucidate the role of this interaction in
synaptogenesis.
Regardless of the mechanism of action of ADAMTS4 in synaptogenesis,
the results presented in this study implicate ADAMTS4 as an important mediator
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of synaptic morphology and therefore, function. If mature spines can be
destabilized and reversed to an immature phenotype, this could lead to new
synaptic connections or perhaps a loss of current synapses. Additionally, this
effect could provide a mechanism for the loss of synapses that occurs in many
inflammatory conditions where ADAMTS expression is increased. At any rate,
this study presents exciting evidence to indicate that the ADAMTSs play an
important role in synaptogenesis that warrants further examination.
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Conclusions
Neural plasticity is a complex phenomenon involving cell proliferation,
migration, neurite outgrowth and synaptogenesis, and while this process is
paramount in the development of the immature CNS, most regions of the adult
CNS exhibit limited neural plasticity in response to experience, attrition or injury.
Understanding how changes in the morphology and function of neurons (and the
nervous system) are activated and regulated is critical to treating injured adult
brains where plasticity is often inadequate for complete reinnervation and
recovery of function. Evidence is emerging to indicate the importance of the
ECM, especially highly negatively charged, CS-containing, PGs, in limiting
regeneration and remodeling responses of the CNS. Additionally, it might be
possible to overcome these limitations of the ECM by degrading either the CS
polysaccharides or by proteolytic cleavage of the core PG proteins. Our studies
sought to determine how proteolytic degradation of the ECM regulates the neural
plastic response, specifically neurite outgrowth and synaptogenesis. In sum,
these studies have shown that astrocytes and neurons cultured in vitro
expressed the PG, brevican, and in astrocytes, the amount of secreted, intact
brevican holoprotein was increased by treatment with TGFß, at least in part via
down regulation of ADAMTS activity. Additionally, we found that astrocytes,
neurons and microglia expressed ADAMTS4 that remained associated with the
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cell surface, and that the ADAMTSs actively cleaved brevican in neurons and
astrocytes. A second series of experiments were conducted to elevate the level
of ADAMTS4 in neuronal cultures which stimulated the extension of neurites from
these neurons. Increasing ADAMTS4 expression in dispersed, cultured neurons
from embryonic rat forebrain increased the length of primary and secondary
neurites, regardless of whether the enzyme was proteolytically active.
ADAMTS4 treatment induced the appearance of phosphorylated ERK1/2 and the
neurite promoting effect was entirely dependent upon activation of the ERK1/2
MAPK pathway, as inhibitors of this pathway nearly completely diminished
ADAMTS4-induced neurite outgrowth. In the final study, treatment with
ADAMTS4 induced alterations in dendritic spine morphology, including an
increase in the proportion of immature dendritic filopodia that was associated
with a concomitant decrease in post-synaptic PSD-95 immunoreactivity. These
results provide the original observation that ADAMTSs can influence neural
plasticity and provide the foundation for further, more detailed investigation as to
the mechanism of how the ADAMTS proteases affect neural plasticity.
At the initiation of these experiments, before directly testing the hypothesis
that ADAMTSs could alter neural plasticity, it was of interest to characterize the
expression patterns of brevican and ADAMTS4, and the proteolytic processing of
brevican in these neural cultures because little to nothing was known about the
deposition of brevican in neural cultures. Conserved sequences near the Nterminus of brevican, aggrecan and versican are the specific sites for ADAMTS
cleavage in these proteins, with alternative MMP cleavage sites with conserved
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sequences, located upstream in the proteins. Using these known sequences,
antibodies can be generated against the neoepitope peptide that is exposed
upon cleavage by the ADAMTSs, and levels of cleaved substrate may be
measured using these antibodies to provide an estimate of the activity of these
proteases. We used the anti-neoepitope antibody for rat brevican cleavage by
the ADAMTSs, anti-EAVESE, in the experiments performed in published Paper
1. This antibody was useful in establishing that the ADAMTSs were active in
cleaving brevican in our cultures (Fig. 3, middle panel) but more importantly, the
measure of EAVESE as a proportion of the level of intact substrate could be
used as an indirect measure of ADAMTS proteolytic activity (Fig. 6, lower
panels).
The above methods were utilized to determine the expression patterns of
brevican and ADAMTS4 in neural cultures so that these cultures could eventually
be used to test our hypothesis. Brevican and its N-terminal cleavage fragment
were detected in the medium of astrocytes and neurons, and several isoforms of
intact brevican were found associated with the cell lysate fraction in these
cultures (Fig. 3, upper panel). No brevican expression was detected in the cell
lysate or medium of microglial cultures (Fig. 3, upper panel). The N-terminal
cleavage fragment of brevican was detected in the medium of neurons and
astrocytes, and not in the cell lysate (Fig. 3, upper and middle panels). The Nterminus of brevican contains a hyaluronan-binding domain and many studies
exist to show that the lecticans bind to hyaluronan at the N-terminus and tenascin
at the C-terminus to form a matrix lattice (Yamaguchi, 2000; Bruckner et al.,
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2003). Since the N-terminal cleavage fragment of ADAMTS4 was detected in the
medium and not cell lysate, it suggests that hyaluronan is not participating in any
matrix formation in these cultures. Brain link proteins (Bral) stabilize the
interactions between hyaluronan and the lecticans (Oohashi et al., 2002; Bekku
et al., 2003), and perhaps these proteins are not present or present in insufficient
concentration to properly stabilize binding. The expression patterns for link
proteins in vitro are currently unknown.
The presence of ADAMTS4-cleaved brevican indicated that these
proteases were present and active in astrocytes and neurons, and ADAMTS4
was detected in the cell lysate fraction of microglia, neurons and astrocytes (Fig.
3, lower panel). ADAMTS4 is produced with an N-terminal pro-domain that
undergoes furin-mediated removal in the trans-Golgi network followed by
secretion as a 68kD protein that is processed C-terminally to yield 53kD and
40kD products (Flannery et al., 2002; Wang et al., 2004). The 53kD form was
detected in the cell lysate of astrocytes and neurons, and several forms were
found in the cell lysate of microglia, all of which coordinated with the bands
detected for human recombinant ADAMTS4 (Fig. 3, lower panel). ADAMTSs are
well established as proteases that bind pericellular region in many cell types in
vitro, and accordingly, ADAMTS4 was not detected in the medium of any of the
cultures examined (Kuno and Matsushima, 1998; Gao et al., 2004).
We established that astrocytes produced a brevican-rich matrix, and we
next attempted to modulate this matrix with cytokines and other factors. Several
studies show increased PG deposition including aggrecan, neurocan and
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versican in response to TGFß in several cell and tissue types (Bassols and
Massague, 1988; Asher et al., 2000; Stokes et al., 2001). Other studies
examining alterations in levels of ADAMTSs resulting from TGFβ treatment are
not as clear and appear to be selective to the protease examined. Others show
that TGFβ decreased ADAMTS1 levels, while increasing ADAMTS4 levels,
although the ADAMTS4 study also revealed increased TIMP activity in
accordance with increased ADAMTS4 (Cross et al., 2005; Ng et al., 2006). We
found that TGFβ increased full-length brevican in the medium of astrocyte
cultures through the inhibition of ADAMTS activity (Figs. 4, 7). Our lab recently
found that lipopolysaccharide (LPS) induced ADAMTS4 protein in vitro
(unpublished findings), and LPS is known to stimulate the secretion of ADAMTS1
(Kuno et al., 1997), indicating that ADAMTS4 may be a protease associated with
inflammatory responses. Since TGFβ is classically a cytokine that correlates
with reduced inflammation, it is logical to find that TGFβ would reduce the activity
of a protease potentiating the inflammatory response.
With characterization studies completed, the next series of experiments
tested the hypothesis that increased cleavage of brevican by ADAMTSs results
in altered neural plasticity. The astrocyte culture, rich in a brevican ECM, was
utilized as a growth substrate for neurons to more closely imitate the inhibitory in
vitro conditions afforded by ECM PGs. PGs are well-known inhibitors of neurite
outgrowth, an effect that is dependent upon both the core protein and CS chains
contained therein (Silver and Miller, 2004; Carulli et al., 2005).
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Mounting evidence indicates that modifications of CS-containing PGs
within the ECM can lead to physiologically relevant changes in the CNS. The
large number of studies of chondroitinase treatment indicate that removal of CS
chains activate plasticity. Modulation of CS-containing PGs activate plastic
responses in the CNS, and chondroitinase treatment to remove the CS chains
from PGs allowed for axonal penetration of a glial scar that was produced in
response to injury (Moon et al., 2001). Additionally, chondroitinase treatment
resulted in reactivation of plasticity in visual cortex after the critical period in rats
undergoing monocular deprivation (Pizzorusso et al., 2006). The mechanism of
inhibition by the core protein is still unclear, however, our lab and others have
postulated that the interactions of CS-containing PGs of the lectican family with
hyaluronan and tenascin, other ECM components, create a meshwork of ECM
that is difficult for cells and neurites to penetrate, and that proteolytic degradation
of the core protein may loosen these associations and afford increased plasticity
(Yamaguchi, 2000); Fig.8, A, B). There is evidence to demonstrate that
proteolysis of the ECM is critical to activate the plastic response. Increased
protease expression occurs during regeneration, neuronal sprouting and
synaptogenesis, and even more compelling, blocking proteolysis of the ECM
impedes neural plasticity (Szklarczyk et al., 2002; Yuan et al., 2002; Reeves et
al., 2003; Kim et al., 2005; Mayer et al., 2005). We attempted to test the
hypothesis that increased proteolysis of CS-containing PGs by ADAMTSs could
alter synaptic plasticity. To accomplish this, neurons were transfected with a
vector to drive the expression of ADAMTS4, or empty vector as a control, and
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applied to a monolayer of astrocytes to provide an inhibitory PG-rich matrix for
which the neurons to extend neurites. Initially, the experimental data supported
this notion, and consistent with our hypothesis, neurons overexpressing
ADAMTS4 extended longer neurites as compared to empty vector transfects
(Fig. 9, E). The increased length of neurites was initially attributed to escalated
cleavage of PGs by ADAMTS4, however our next experiments suggested that
proteolysis of ECM proteins by the ADAMTSs may not be important in the
increases seen in neurite outgrowth. To test this, we performed the experiment
again but plated these transfected neurons on a permissive poly-l-lysine/laminin
substrate where the increased expression of ADAMTS4 would not have
abundant substrate produced by astrocytes to cleave, and interestingly, the same
results were obtained (Fig. 10, E). Neurons over-expressing ADAMTS4
extended longer neurites, regardless of whether they were plated on an astrocyte
monolayer secreting inhibitory CS-containing PGs or permissive poly-llysine/laminin substrate (Figs. 9-10). This was certainly surprising and indicated
that the mechanism proposed in our hypothesis was not supported. We next
reformulated our hypothesis to presume that ADAMTS4 could exert biological
effects in the absence of its proteolytic capacity. Although there was no evidence
to show that ADAMTSs could act in a non-proteolytic fashion, there were studies
indicating that MMPs, a family of related proteases, could transduce cell signals
in the absence of proteolytic activity. For example, MMP-1 interacts with integrin
receptors to stimulate dephosphorylation of Akt and induce apoptosis (Conant et
al., 2004), and perhaps ADAMTSs could act in a similar fashion. To more
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directly test the notion that ADAMTS4 increases neurite length in the absence of
proteolysis of CS-containing PGs, we repeated the previous experiment with an
added parameter: a vector to drive the expression of proteolytically inactive,
mutant ADAMTS4 protein (Gao et al., 2004), and plated these neurons on poly-llysine/laminin substrate. Surprisingly, mutant ADAMTS4 significantly increased
neurite outgrowth in a manner similar to native human ADAMTS4-transfects (Fig.
11, G), suggesting the possibility that ADAMTS4 was binding to a cell surface
receptor to induce intracellular signals that resulted in longer neurite lengths.
Interestingly, the thrombospondin motif and spacer region contained within
ADAMTS family members mediate substrate binding (Kuno and Matsushima,
1998; Kashiwagi et al., 2004), and perhaps this interaction may be the means
through which ADAMTS4 is binding to an unknown cell surface receptor to
activate signaling.
Given the domains of ADAMTS4 and the binding patterns of proteins with
similar domains, there are many cell surface receptors that ADAMTS4 could bind
to transduce cell signals to stimulate neurite outgrowth. ADAMTS4 contains TSP
motifs, and TSP itself induces neurite outgrowth through the activation of
integrins (Neugebauer et al., 1991; DeFreitas et al., 1995), which are well-known
cell surface signal transducers. Interestingly, this effect could be blocked by
heparin, indicating that the binding may be mediated by a PG containing heparan
sulfate or a sulfated glycolipid (Neugebauer et al., 1991). Clearly TSP increases
neurite outgrowth, but can a TSP motif act in a similar way? Studies with the
protein SCO-spondin, with 26 TSP repeats, indicate that this is the case. This
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protein increases neurite outgrowth in a variety of neurons and neuron-like cells,
and this action is mediated by the interaction of a sequence in the TSP motif,
WSGWSSCSRSCG, with α1β1 integrin (Monnerie et al., 1998; Gobron et al.,
2000; El-Bitar et al., 2001; Bamdad et al., 2004). Thus, perhaps the TSP motifs
of ADAMTS4 could act similarly to activate integrin signaling to increase neurite
outgrowth. We attempted preliminary experiments with integrin antibodies to
block integrin ligands and signal transduction to determine if this could attenuate
ADAMTS4-mediated increases in neurite outgrowth, and encountered difficulties
when basal neurite outgrowth was inhibited (data not shown). Thus, it may be
difficult with this type of experiment to determine which integrins, if any, play a
role in signaling via the ADAMTSs to increase neurite outgrowth if these integrins
are essential for normal neurite outgrowth.
Interactions of ADAMTS4 with other moieties may be the means through
which this protease is stimulating cell signaling. The ADAMTSs bind ECM
components like heparan sulfate (HS) and CS, and in fact, this association is
important for substrate binding and cleavage (Tortorella et al., 2000; Flannery et
al., 2002; Kashiwagi et al., 2004). ADAMTS4 binds the HS of syndecan-1, but it
is unknown whether this binding is necessary to induce cell signals (Gao et al.,
2004). Neurocan, typically inhibitory to neurite outgrowth, when bound to
HSPGs, promotes neurite outgrowth, although it is unknown whether this
interaction is a sequestering phenomena or whether signals are induced through
the interaction between neurocan and HSPGs (Akita et al., 2004). Heparinbinding growth associated molecule (HB-GAM) binds syndecan-3 to increase
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neurite outgrowth, an association that is mediated by the heparan sulfate chains
of syndecan-3 (Raulo et al., 1994; Kinnunen et al., 1996). Furthermore,
syndecans play important roles during development to promote neuronal cell
migration (Toba et al., 2002). Thus, it is plausible that ADAMTS4 could be
interacting with syndecan HS to promote neurite outgrowth.
We next attempted to elucidate the cell signals induced by ADAMTS4 to
examine whether the intracellular signaling pathways known to be involved in
ligand-induced neurite plasticity were also stimulated by the action of the
ADAMTSs. Human recombinant ADAMTS4 was added to the culture medium of
neurons growing on poly-l-lysine/laminin substrate, and the cell lysate collected
at 20, 40 and 60 minutes after addition to determine the levels of various signals
that were induced by ADAMTS4 treatment (Figs. 13, 14). Analysis of alterations
in general protein phosphotyrosine levels revealed changes in several proteins
(Fig. 13, A-F), and analyses with antibodies specific to phospho-ERK1/2 revealed
that there were increases in activated, phospho-ERK1/2 MAPK in neuronal
cultures treated with human recombinant ADAMTS4 compared to vehicle-treated
controls (Fig. 14, A-D). It is important to note, however, that the human
recombinant enzyme preparations utilized in these studies were purified at
Roche Biosciences, and while these proteases are presumed to be pure, the
exact protein character of the prerarations is unknown, and the possibility that the
effects detected in response to ADAMTS treatment are due to a contaminating
substance cannot yet be eliminated. Further studies are necessary to fully
investigate this possibility. More importantly, blockade of the MAPK pathway
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attenuated the ADAMTS-mediated increases in neurite outgrowth (Fig. 15, A-C),
suggesting a vital role for the ERK MAPK pathway in ADAMTS-induced neurite
outgrowth.
Activation of the MAPK pathway is important in inducing neurite outgrowth
in a variety of neuronal-like cell types such as neuroblastoma cells, NG108-15
cells and hippocampal neurons (Schmid et al., 2000; Gerecke et al., 2004; Gu et
al., 2005), but can interactions with syndecans or integrins, (as proposed cell
surface receptors for ADAMTS4) stimulate the MAPK pathway to modulate
neurite outgrowth? The α1 integrin subunit binds protein tyrosine phosphatase
(PRL-3) to activate ERK1/2 and increase neurite outgrowth (Peng et al., 2006).
Additionally, connective tissue growth factor (CCN-2), which like ADAMTS4,
possesses a thrombospondin type-1 motif, binds syndecan-2 to activate ERK1/2
signaling (Chen et al., 2004), so ADAMTS4 could interact with syndecans or
integrins to stimulate ERK1/2 signaling. Furthermore, interactions of ADAMTS4
with PGs may even mediate this effect. Basic fibroblast growth factor (FGF)-2
binds HS on the PG agrin to activate ERK1/2 signaling and alter neurite
outgrowth in PC-12 cells (Kim et al., 2003), although this may be an HS selective
event. ADAMTS4 could orient FGF-2 binding to HS on agrin, however, agrin
expression is low in the CNS relative to the PNS, so this may be unlikely or could
occur via another PG that contains HS in the CNS. The cell surface receptor
activated by binding ADAMTS4 is currently unknown, and at this point, our
research only allows for speculation, so further studies are needed to determine
the identity of this receptor.
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Since ADAMTS4 increases neurite outgrowth, it clearly was of interest as
to whether the ADAMTSs may influence other parameters of morphological
neural plasticity, such as synapse-associated plasticity. It is largely unknown
what role ECM proteases play in synaptogenesis and synaptic reorganization,
although indirect evidence indicates that these proteases may be important in
this capacity since ADAMTSs are increased during periods of synaptic
restructuring in the adult nervous system (Yuan et al., 2002; Mayer et al., 2005).
Alterations in the morphology of dendritic spines are correlated with functional
and structural changes at the post-synaptic density and more generally, can
influence behavior (Engert and Bonhoeffer, 1999). Thus, to analyze alterations
in dendritic spine morphology in response to ADAMTS4, neuronal cultures were
treated with 50nM human recombinant ADAMTS4 for 2-3 days, the neurons were
fixed with 4% paraformaldehyde and immunostained for actin, a protein whose
polymerized filaments are abundant and concentrated in dendritic spines.
Dendritic spines were visualized by confocal microscopy, counted in segments of
10µm, and protrusion length and the diameters of the neck and head of the
protrusion were measured. Significant increases in the overall lengths of
dendritic protrusions were detected in response to ADAMTS4 treatment (Fig. 16,
D). Increased protrusion length is an indication of immaturity, and to further
investigate the possibility that ADAMTS4 was inhibiting the maturation of
dendritic spines, specific morphological types of spines were examined.
Dendritic spines may begin as filopodia that are seeking a synaptic contact, and
these may disappear or mature into a dendritic spine, which may be subdivided
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into several morphological types: thin, mushroom and stubby, with thin being the
most immature of the three, and stubby being the most mature and stable (Ziv
and Smith, 1996; Fiala et al., 1998; Harris, 1999). ADAMTS4 treatment resulted
in increased percentage of filopodia, in both young and mature cultures (Fig. 17),
indicating that ADAMTS4 may be important in preventing the maturation of
synapses or in inducing the formation of new filopodia. This increase in filopodia
was accompanied by decreases in PSD-95 immunoreactivity in the post-synaptic
density of neurites of neurons transfected with native or mutant ADAMTS4 (Fig.
22, E). Since these neurons were grown on permissive poly-l-lysine/laminin
substrate and since the mutant ADAMTS4 construct yielded similar results, it is
likely that the effects seen on synaptogenesis with ADAMTS4 treatment is
independent of proteolysis, however, further studies are needed to determine
whether this is the case or not. Regardless of how ADAMTS4 is acting to alter
synaptic maturation, the results presented in paper 3 implicate ADAMTS4 as an
important mediator of synaptic morphology and therefore, function. These
actions of ADAMTS4 may have wide-range consequences, for instance, if
mature spines can be destabilized and reversed to an immature phenotype, this
could lead to new synaptic connections or perhaps a loss of current synapses.
Additionally, this effect could provide a mechanism for the loss of synapses that
occurs in many inflammatory conditions where ADAMTS expression is increased.
At any rate, the effect of ADAMTS4 in altering synaptogenesis is clearly novel
and potentially significant. Further studies are required to determine how
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ADAMTS4 is acting in the exquisite regulation of synapse formation and
maintenance.
As with increases in neurite outgrowth, it is possible that the effects of
ADAMTS4 on synapse morphology and function are mediated by the integrins.
Integrins mediate effects on synaptic maturation, LTP, and NMDA receptor
responses (Chavis and Westbrook, 2001; Chan et al., 2003; Lin et al., 2003;
Bernard-Trifilo et al., 2005). Even more interesting, hippocampal neurons treated
with an RGD-containing peptide to activate integrins exhibit increased spine
length and increased numbers of filopodia, similar to the results of the studies in
Paper 3 (Shi and Ethell, 2006). Alternatively, a syndecan family member could
play a role in mediating this effect, since syndecan-2 has been shown to be a key
regulator of dendritic spine formation. Induction of syndecan-2 expression in
immature hippocampal neurons resulted in clustering of syndecan-2 and the
formation of mature dendritic spines (Ethell and Yamaguchi, 1999). This effect
was regulated by EphB2 receptor tyrosine kinase, which phosphorylates
syndecan-2 (Ethell et al., 2001). Again, since ADAMTS4 may be able to bind
and/or activate integrin receptors or syndecan HSPGs, these associations may
play a role in dendritic spine formation.
This manuscript provides evidence that ADAMTS4 increases neurite
lengths and prevents maturation of dendritic spines, however, it is currently
unknown how the secretion of ADAMTSs in vivo affects neural plasticity, and
whether or not ADAMTSs are critical for neurite outgrowth and synaptogenesis.
ADAMTS4 is secreted by astrocytes, neurons and microglia, and these cells
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could potentially alter neural plasticity through the production of ADAMTS4 or
other ADAMTSs (Fig. 23). While it is clear that ADAMTS4 is secreted and binds
the cell surface, the cellular origin of such ADAMTS4 protein is unknown, and
could potentially be secreted from neurons at the dendrite and/or axon to alter
neurite outgrowth (A). Furthermore, since astrocytes and microglia express
ADAMTS4, the role of these cells in ADAMTS-mediated neurite outgrowth is
possible and cannot be ignored (B, C). In addition to neurite outgrowth, dendritic
spine maturation could be altered by secretion of ADAMTS4 from neurons (D),
astrocytes (G) or microglia (H). Furthermore, ADAMTSs may exert effects on
other CNS processes like astrocyte reactivity and microglial migration and
invasion where a remodeling of the CNS is necessary for these processes to
occur (E, F). Although we provide evidence to indicate that the ADAMTSs
mediate neural plasticity in a non-proteolytic manner, there may be a balance
between the proteolytic and non-proteolytic actions of ADAMTS4 in regulating
neural plastic processes.
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Figure. 23: ADAMTS4 mediates neural plasticity. Neurons, astrocytes and
microglia secrete ADAMTS4 and potentially mediate neurite outgrowth and
synaptogenesis in vivo (A-D, G, H). Furthermore, secretion of ADAMTS4 by
astrocytes and microglia may play a role in astrocyte reactivity (E) and microglial
migration and invasion (F).
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In sum, the studies presented here provide evidence that ADAMTS4 can
modulate neural plasticity in a non-proteolytic-dependent manner. These are the
very first studies to indicate that ADAMTSs can act in a capacity other than a
protease, and even more exciting, that they modulate neurite outgrowth and
synaptogenesis. Further studies are needed to elucidate the exact function of
ADAMTS4 in these processes, and there is still much work to be done to identify
the cell surface receptor and the entire signal cascade that remains obscured
between ADAMTS4 addition and alterations detected in neurite outgrowth and
synaptogenesis. Once elucidated, perhaps the ADAMTSs can be utilized as
therapeutic targets in patients with traumatic brain or spinal cord injury where the
formation of a glial scar in response to the injury results in an inhibitory
environment that hampers plasticity and complete recovery of the CNS. This
resistance to plasticity in the adult brain perhaps could be altered with ADAMTS4
treatment. Of course, there is a great deal of work to be done to understand the
exquisite regulation between protecting established synapses and forming new
ones. In a brain that is injured, the outgrowth of neurites and filopodia could
provide a means for new synaptic contacts and recapture of function, but of
course, it is paramount to regulate this process to prevent the formation of
aberrant connections. Furthermore, if ADAMTS4 induces the reversal of mature
contacts, this could result in the loss of function and memories, and be very
destructive, so it will be extremely exciting to research this area further to
determine the exact roles for the ADAMTSs in neural plasticity and in treatment
of the damaged CNS. Overall, these studies provide compelling evidence that
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ADAMTS4 acts in a non-proteolytic manner to increase neurite outgrowth and
prevent synapse maturation in vitro. These are the first experiments to implicate
the importance of ADAMTS4 in neural plasticity, and even more surprising, that
these effects are mediated by cell signaling rather than proteolysis.
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